WO2003103656A1 - O−置換ヒドロキシアリール誘導体 - Google Patents
O−置換ヒドロキシアリール誘導体 Download PDFInfo
- Publication number
- WO2003103656A1 WO2003103656A1 PCT/JP2003/007127 JP0307127W WO03103656A1 WO 2003103656 A1 WO2003103656 A1 WO 2003103656A1 JP 0307127 W JP0307127 W JP 0307127W WO 03103656 A1 WO03103656 A1 WO 03103656A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- formula
- hydrocarbon
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/803—Processes of preparation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D269/00—Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups C07D261/00 - C07D267/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Definitions
- the present invention relates to an inhibitory effect on the production and release of inflammatory site power-ins such as interleukin (IL) -1, IL-16, IL-8, and tumor death factor (TNF- ⁇ ), and an inhibitory effect on NF- ⁇ activation.
- IL interleukin
- IL-8 tumor death factor
- TNF- ⁇ tumor death factor
- a pharmaceutical having:
- Inflammation is a fundamental defense mechanism against a variety of invasions, where the inflammatory site forces interleukin (IL) -11 and TNF- ⁇ (tumor death factor) play an important role It is known.
- IL interleukin
- TNF- ⁇ tumor necrosis factor
- This transcription factor is a protein called NF- ⁇ (sometimes referred to as ⁇ F ⁇ ) (“Nucleic Acids Research”, (UK), 1986 , Vol. 14, No. 20, p. 7897-7914; “Cold Spring Harbor Symposia on Quantitative Biology", (USA), 1986 Year, Vol. 51, Part 1, .61 1—624).
- This NF- ⁇ is a heterodimer (also called a complex) of p65 (also called Re1A) and p50 (also called NF_KB_1), and is usually I in the absence of external stimuli.
- I_ ⁇ B Binds to ⁇ B and exists in the cytoplasm as an inactive form.
- I_ ⁇ B is phosphorylated by various external stimuli (oxidative stress, cytokinin, lipopolysaccharide, Willyls, UV, free radicals, protein kinases, etc.), and is ubiquitinated and subsequently degraded by proteasome Be done (Jeans and Loppment (Genes & Development) J, (USA), 1995, Vol. 9, No. 22, p. 2723-2735).
- NF_ ⁇ B which is away from I- ⁇ B, rapidly translocates into the nucleus and plays a role as a transcription factor by binding to a promoter region having an NF- ⁇ recognition sequence.
- IKK contains IKK- ⁇ (also called IKK1) and IKK_i3 (also called IKK2), which are very similar to each other, and these two form a complex to form I ⁇ Is known to phosphorylate I ⁇ by direct binding to the cell (Science J, (USA), 1997, Vol. 278, p. 866-869; “Cell”, (USA), 1997, Vol. 91, No. 2, p. 243-252).
- Darcocorticoids such as dexamethasone (the steroid fallmons) inhibit NF- ⁇ B activation by binding to their receptors (called darcocorticoid receptors), although the “Science” , (USA), 1995, Vol. 270, ⁇ ⁇ 283-286), prolonged use due to serious side effects such as worsening of infectious disease, occurrence of peptic ulcer, decrease in bone density, and central action Not suitable for
- the isoxazole drug leflunomide which is an immunosuppressant, also has NF-B inhibitory activity (Journal of Immunology), (USA), 1999, Vol. 162, No.
- ⁇ F— ⁇ activation inhibitors include substituted pyrimidine derivatives. No. 51 23 99, and “Journal of Medicinal Chemistry”, (United States), 1998, Vol. 41, No. 4, p.
- N-phenylsalicylamide derivatives Pharmaceuticals are disclosed in European Patent No. 0221121, JP-A-62-99329, and US Pat. No. 6,178,859 as anti-inflammatory agents. Although ⁇ - phenylalanine salicylamide derivatives having the WO 99/65499 Patent Panfuretsuto NF-? Kappa B inhibitory activity are disclosed, the compound being measured actually anti-inflammatory activity or NF_ ⁇ ⁇ inhibitory activity There are few studies on the structure of the aniline moiety with only limited substituents and substitution positions. International Publication No.
- 02/49632 pamphlet discloses that a hydroxyaryl derivative containing a paraarylsalicylamide derivative has an NF- / c ⁇ inhibitory action. Regarding the substituted product, only the description of the ⁇ -substituted salicylamide ⁇ ”acetyl compound is available.
- WO02 / 076918 pamphlet is disclosed as an N-phenylsalicylamide derivative.
- International Publication No. 02Z0513977 discloses an N-phenylsalicylamide derivative as a cytokine production inhibitor. Disclosure of the invention
- An object of the present invention is to provide a medicine having an activity of inhibiting NF- ⁇ activation.
- the present inventors synthesized 0-substituted derivatives of various hydroxyaryl derivatives and examined the inhibitory effect of NF- ⁇ B activation under TNF- ⁇ stimulation by a reporter assay, and as a result, The present inventors have found that substituted hydroxyaryl derivatives have a strong activity of inhibiting ⁇ F- ⁇ activation, and have completed the present invention.
- X represents a linking group having 2 to 5 main chain atoms (the linking group may have a substituent);
- ⁇ represents an optionally substituted acyl group (however, excluding an unsubstituted acetyl group and an unsubstituted acryloyl group), or an optionally substituted C i C alkyl group. Or a bond to a linking group X to form an optionally substituted ring structure,
- E represents an aryl group which may have a substituent or a heteroaryl group which may have a substituent
- Ring Z is represented by the formula O—A (where A is as defined above) and the formula X—E (wherein X and E have the same meaning as defined above, and may further have a substituent in addition to the group represented by the formula or O-A (where A is as defined above) And a compound represented by the formula —X—E (wherein, X and E have the same meanings as defined above) and may further represent a heteroarene that may have a substituent. And a pharmacologically acceptable salt thereof, and a substance comprising a substance selected from the group consisting of hydrates and solvates thereof as an active ingredient, and providing a medicament having a NF- / cB activation inhibitory action. It is.
- Preferred medicaments of the invention include:
- the above-mentioned medicament comprising, as an active ingredient, a salt thereof, and a substance selected from the group consisting of hydrates and solvates thereof,
- Substituent group ⁇ A hydrocarbon monocarbyl group which may have a substituent, a heterocyclic-carboyl group which may have a substituent, or a substituent which may have a substituent Hydrocarbon-carboxyl group, hydrocarbon-sulfonyl group which may have a substituent, sulfamoyl group which may have a substituent, sulfoyl group which may have a substituent A force phono group which may have a substituent, and a rubamoyl group which may have a substituent
- the above medicine comprising as an active ingredient a substance selected from
- the ring ⁇ is CeCi. (Wherein A is as defined in formula (I)) and X-E (where X and E are formula (I)) ) And pharmacologically acceptable salts thereof, and hydrates and solvates thereof.
- the above-mentioned medicines comprising as an active ingredient a substance selected from the group consisting of
- the above-mentioned medicament comprising, as an active ingredient, a substance selected from the group consisting of (7) Ring Z force Formula I O—A (where A is as defined in general formula (I)) and X—E (where X and E are general formulas (I) From the group consisting of a benzene ring having a halogen atom in addition to the group represented by, a pharmacologically acceptable salt thereof, and a hydrate and solvate thereof.
- Ring Z force S (where A has the same meaning as defined in general formula (I)) and formula X—E (where X and E are general formulas (I)
- a naphthalene ring which may further have a substituent in addition to the group represented by the above formula, and pharmacologically acceptable salts thereof, and hydrates and solvates thereof.
- the above-mentioned medicine which comprises, as an active ingredient, a substance selected from the group consisting of:
- CeC in which E may have a substituent Selected from the group consisting of an aryl group or a 5-membered heteroaryl group which may have a substituent, and pharmacologically acceptable salts thereof, and hydrates and solvates thereof.
- (10) E is selected from the group consisting of a compound which is a phenyl group which may have a substituent, a pharmacologically acceptable salt thereof, and a hydrate and a solvate thereof.
- the above medicines containing a substance as an active ingredient,
- E is a thiazolyl group which may have a substituent, a pharmacologically acceptable salt thereof, and a hydrate and a solvate thereof.
- a 1 represents an optionally substituted acyl group (however, excluding an unsubstituted acetyl group and an unsubstituted acryloyl group), or an optionally substituted acryloxymethylene group;
- E 1 represents an aryl group which may have a substituent or a heteroaryl group which may have a substituent
- Ring Z 1 is represented by the formula _0—A 1 (where A 1 is as defined above) and the formula —CONH-E 1 (where E 1 is as defined above)
- a 1 is an N, N-disubstituent rubamoyl group (the two substituents of the carbamoyl group may be joined together to form a substituent together with the nitrogen atom to which they are bonded; Or a salt thereof, or a hydrate or solvate thereof,
- the ring Z 1 is represented by the formula O—A 1 (where A 1 is the same as defined in the general formula (1-1)) and the formula—CONH—E 1 (where E 1 Is a benzene ring further having a halogen atom in addition to the group represented by the general formula (1-1), or a salt thereof, or a hydrate or a solvent thereof.
- the ring Z 1 is a group represented by the formula O—A 1 (where A 1 has the same meaning as defined in the general formula (1-1)) and a group CONH—E 1 (where E 1 is The above-mentioned compound or a salt thereof, which is a naphthalene ring which may further have a substituent, in addition to the group represented by the general formula (1-1), which has the same meaning as the definition in the general formula (1-1), or a hydrate or a hydrate thereof Their solvates,
- the present invention provides the compound or a salt thereof, or a hydrate or solvate thereof, wherein E 1 is a thiazolyl group optionally having substituent (s). From another viewpoint, a medicament containing the compound of the above (1) to (11) or a salt thereof, or a hydrate or a solvate thereof;
- kappa beta activation in a mammal including bets of the above (1) compound or a salt thereof or a hydrate thereof or their solvate, to (1 1)
- a method comprising administering an effective amount of a substance to a mammal, including a human.
- any of a fluorine atom, a chlorine atom, a bromine atom and an iodine atom may be used unless otherwise specified.
- hydrocarbon group examples include an aliphatic hydrocarbon group, an aryl group, an arylene group, an aralkyl group, a crosslinked cyclic hydrocarbon group, a spirocyclic hydrocarbon group, and a terpene hydrocarbon.
- aliphatic hydrocarbon group for example, a linear or branched monovalent or divalent non-valent group such as an alkyl group, an alkyl group, an alkynyl group, an alkylene group, an alkenylene group and an alkylidene group is exemplified.
- Cyclic hydrocarbon group saturated or unsaturated monovalent or divalent alicyclic group such as cycloalkyl group, cycloalkenyl group, cycloalkenyl group, cycloalkyl monoalkyl group, cycloalkylene group, cycloalkylene group, etc. And a hydrocarbon group.
- Alkyl group includes, for example, methyl, ethyl, ⁇ -propyl, isopropyl, ⁇ -butynole, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopenpentole, 2-methinolebutynole, 1-methylbutyl, neopentyl, 1,
- alkenyl group examples include, for example, Bier, Proper 1-yl, Alinole, Isoprobe, Buta_1-Yen-1-inole, Buta-2-en-1-ynole, Puta 1 3 _ 1 _ 1 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _
- alkynyl group examples include, but are not limited to, ethel, prop-l-in-l-yl, prop-l-l-in-l-yl, pig-l-l-l-in-l-ll, pig-l-l-in-l-l —Inore, 1-Mechinore Proper 2—Inn 1-11, Penter 1-in-1 1-inore, Penter 4-in-1 1_inore, Hexa _1_in-1 1-inore, Hexar 5-in-1 One, one hepter one one one one one, one hepter six—one one one one, one ota one one one one, one octa seven, one one one one one one, one non one, one one one one one , Nonnar 8—In 1 1_Ill, Deca 1—In 1 1—Ill, Decah 9 1 In—1—Iinore, ⁇ indeka 1 1 In 1 1 ⁇ Iinore, ⁇ indeka 1
- alkylene group examples include methylene, ethylene, ethane-1,1, diyl, propane-1,3-diyl, propane-1,2-diyl, propane-1,2,
- Examples thereof include a C i C s linear or branched alkylene group such as 1,6-diyl and 1,1,4,4-tetramethylbutane-1,4-diyl.
- arkenylene group examples include, for example, ethene-1,2-diyl, propene-1,
- alkylidene group for example, methylidene, Echiriden, propylidene, isopropylidene, butylidene, pentylidene, and linear or branched alkylidene group of C 1 -C 6, such as cyclohexylidene to.
- cycloalkyl group examples include C 3 to C 8 cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentynole, cyclohexynole, cycloheptyl, and cyclooctynole.
- the above “cycloalkyl group” may be condensed with a benzene ring, a naphthalene ring, or the like, for example, 1-dandanyl, 2-indanyl, 1,2,3,4-tetrahydronaphthalene-1 Groups such as 1,2,3,4-tetrahydronaphthalene-1-yl and the like.
- cycloalkenyl group examples include 2-cyclopropene-11-yl, 2-cyclobutene-1-ynole, 2-cyclopentene-1-ynole, 3-cyclopentene-11-yl, and 2-cyclohexene-1-ene And C 3 -C 6 cycloalkenyl groups such as 1-yl, 3-cyclohexene-1-yl, 1-cyclobutene-11-yl, and 1-cyclopentene-11-yl.
- cycloalkenyl group may be condensed with a benzene ring, a naphthalene ring, or the like.
- a benzene ring for example, 1 f dandyl, 2- ⁇ f dandyl, 1, 2, 3, 4-tetrahydronaphthalene 1 —Yl, 1,2,3,4-tetrahydronaphthalene-121-yl, 1-indenyl, 2-indenyl and the like.
- cycloalkanegenyl group examples include, for example, 2,4-cyclopentagen-111-yl, 2,4-cyclohexane-gen-1-1-inole, and 2,5-cyclohexan-hexyl-1-yl.
- the above “cycloalkanegenyl group” may be condensed with a benzene ring, a naphthalene ring or the like, and examples thereof include groups such as 1-indur and 2-indur.
- cycloalkyl-alkyl group examples include groups in which one hydrogen atom of the “alkyl group” has been substituted with a “cycloalkyl group”.
- cycloalkylene group examples include, for example, cyclopropane-1,1, diyl, cyclopropane-1,1,2-diyl, cyclobutane-1,1,2-diyl, cyclobutane-1,2-diinole, cyclobutane-1,1,3-diinole, Cyclopentane-1,1-diyl, Cyclopentane1-1,2-diyl, Cyclopentane-1,3-diynole, Cyclohexane1-1,1-diyl, Cyclohexane-1,2-diyl, Cyclohexane-1 1,3-diynole, cyclohexane-1,4-diynole, cycloheptane-11,1-diyl, cycloheptane_1,2-diyl, cyclooctane-1,1-diyl, cyclooc
- cycloalkylene group examples include 2-cyclopropene-1,1 diyl, 2-cyclobutene-11,1 diyl, 2-cyclopentene-1,1,1-diyl, 3-cyclopentene_1, 1-diyl, 2-cyclohexene-1 1,1 dinole, 2-cyclohexene-1 1,2-diynole, 2-cyclohexene 1-1,4-diyl, 3-cyclohexene 1-1,1 diyl
- C 1 -C 6 -cycloalkylene groups such as 1,1-cyclobutene-1,1,2-diyl, 1-cyclopentene-1,1,2-diynole, and 1-cyclohexene-1,1,2-diynole.
- the "Ariru group” a monocyclic or condensed polycyclic aromatic hydrocarbon group, for example, phenyl, 1 one-naphthyl, 2-naphthyl, anthryl, Fuenantoriru, of C 6 -C 1 4 such Asenafuchireniru Aryl group.
- aryl group is the above “C 3 -C 8 cycloalkyl group”, “C 3 -C 6 cycloalkenyl group”, or “C 5 -C 6 cycloalkenyl group”. And may be condensed with, for example, 4- ⁇ -dandanyl, 5-indanyl, 1,2,3,4-tetrahydronaphthalene-15-yl, 1,2,3,4-tetrahydronaphthalene 1 6-yl, 3-acenaphthenyl, 4-acenaphthenyl, inden 41-yl, inden 1-5-inore, inden 1-6-inole, inden 7-isle, 4-4 fenarennore, 5-fenarennore, 6-phenareninore, 7 —Huenareninole, 8—Huenaré And groups such as 9-phenylenenyl and the like.
- arylene group examples include 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, naphthalene-1,2-diyl, naphthalene-1,3-diethylene, Naphthalene-1, 4-diinole, naphthalene-1, 5-diinole, naphthalene-1, 6-diyl, naphthalene-1, 7-diyl, naphthalene-1, 8-diyl, naphthalene-1, 3-diyl ⁇ /, naphthalene One two, four ginole, one naphthalene two,
- aralkyl group examples include groups in which one hydrogen atom of the “alkyl group” has been substituted with the “aryl group”.
- Examples thereof include C 7 -C 16 aralkyl groups such as 6- (1-naphthyl) hexyl and 6- (2-naphthyl) hexyl.
- bridged cyclic hydrocarbon group examples include groups such as bicyclo [2.1.0] pentyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.1] octyl and adamantyl.
- groups such as bicyclo [2.1.0] pentyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.1] octyl and adamantyl.
- spirocyclic hydrocarbon group examples include groups such as spiro [3.4] octyl and spiro [4.5] deca 1,6-genyl.
- Examples of the “terpene-based hydrocarbon” include groups such as geralh, neryl, linalyl, phytyl, menthyl, and bornyl.
- Examples of the “halogenated alkyl group” include groups in which one hydrogen atom of the “alkyl group” has been substituted with a “halogen atom”. Examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethinole, and dichloromethinole.
- Trichloromethinole bromomethylenole, dibromo'methinole, tribromomethinole, eodomethy ⁇ ⁇ jodomethyl, triodomethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl, hepta C 1 -C 6 straight or branched chain substituted with 1 to 13 halogen atoms such as fluoropropyl, heptafluoroisopropyl, nonafluorobutyl, and And an alkyl group.
- heterocyclic group includes, for example, at least one or more heteroatoms selected from oxygen, sulfur and nitrogen atoms as atoms (ring atoms) constituting a ring system.
- a monocyclic or condensed polycyclic heteroaryl group and at least one or three heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom as atoms (ring atoms) constituting a ring system.
- monocyclic or condensed polycyclic non-aromatic heterocyclic groups are examples of monocyclic or condensed polycyclic non-aromatic heterocyclic groups.
- Examples of the “monocyclic heteroaryl group” include, for example, 2-furyl, 3-furyl, 2-phenyl, 3-phenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-oxazolyl, 4-oxazolyl, 5 —Oxazolyl, 3-isoxazolyl, 4 —isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl,
- Examples of the “fused polycyclic heteroaryl group” include, for example, 2-benzofuranyl, 3-benzofurananol, 4-benzofuranole, 5-benzofuranole, 6-benzofuranole, 7-benzofuranole, and 11-isobenzofura. 2 nore, 4 1 isobenzo bra 2 nore, 5-Isobenzofuraninole, 2-benzo [b] phenyl, 3-benzo [b] phenyl, 4-benzo [b] cher, 5-benzo [b] chenolin, 6-ben Ezo [b] Chennore, 7-Venzo [b] Chennore, 11 Benzo [c] Chennore, 4-benzo
- 2-benzothiazolinole 4-benzothiazolyl, 5_benzothiazolyl / ⁇ , 6-benzothiazolyl, 7_benzothiazolyl, (1,2-benzoisothiazole) 1-3-yl, (1,2-benzene Zoisothiazole) 14-yl, (1,2-benzisothiazole) 1-5-inole, (1,2-benzoisothiazole) 16-yl, (1,2 benzoisothiazole) (Zonore) 1 7-inole, (2,1 Benzoisothiazonore) 1 3_ yl, (2,1 Benzoisothiazole) 1 4_yl, (2, 1 Zonzosothia zonore) 1-5-inole, (2,1-benzoisothiazole) 1-6_yl, (2,1 Benzoisothiazole) 1-7-yl, (1,2,3-Benzoxadiazole) 1-4-yl, (1
- “monocyclic non-aromatic heterocyclic group” for example, 1-aziridinyl, 1-azeti Diel, 1-Pyrrolidinyl, 2-Pyrrolidinyl, 3-Pyrrolidinyl, 2-Tetrahydrofuryl, 3-Tetrahydrofuryl, Thiolanyl, 1-Imidazolidinyl, 2-Imidazolidinyl, 4-Imidazolidinyl, 1-Vilazolidinyl, 3-Vilazolidinyl, 4-Vinyl , 1- (2-pyrroliel), 1- (2-imidazolinyl), 2- (2f-midazolyl), 1- (2-birazolinyl), 3- (2-pyrazolinyl), piridino , 2-piridininole, 3-piridininole, 4-piridininyl, 1-formopiperidinole, 2-tetrahydrovilla-norre, monoleforino,
- Examples of the “condensed polycyclic non-aromatic heterocyclic group” include 2-quinuclidinyl, 2-chromatin, 3-chrominole, 4-chrominole, 5-chrominole, and 6-chrominole Nore, 7_Chroma Nore, 8—Chroma Nore, 1 ⁇ ⁇ Sochroma Nore, 3_IsoChroma Nore, 4—Isochromainole, 5_Isochroma Nore, 6—Isochroma Nole, 7—IsoChroma Nore, 8 — Isochrominole, 2—Chrome 2, 3—Chrome 2, 4 Chroma 2, 5—Chrome 2, 6—Chrome 2, 7 1 -1,8-thiochromanil, 1-isothiochromanole, 3_isothiochromanole, 4-isothiochromanole, 5-isothiochromanil, 6-isothiochromanil, 7-isothiochromane, 8-isothi
- heterocyclic group in addition to a nitrogen atom having a bond, a heteroatom selected from an oxygen atom, a sulfur atom, a nitrogen atom and the like as an atom (ring atom) constituting a ring system.
- a monocyclic or condensed polycyclic non-aromatic heterocyclic group which may have 1 to 3 heteroatoms selected from a sulfur atom and a nitrogen atom is referred to as a ⁇ cyclic amino group ''
- Aryl group “cycloalkylene group”, “cycloalkenedylene group”, “arylene group”, “bridged cyclic hydrocarbon group”, “spirocyclic hydrocarbon group”, and “heterocyclic group” And referred to as “cyclic group”. Further, among the “cyclic groups”, “aryl groups”, “arylene groups”, “monocyclic heteroaryl groups”, and “fused polycyclic heteroaryl groups J” are collectively referred to as “aromatic groups”. A cyclic group ".
- hydrocarbon monooxy group a group in which a hydrogen atom of the “hydroxy group” has been replaced with a “hydrocarbon group” can be mentioned.
- hydrocarbon the same groups as the above “hydrocarbon group” can be mentioned.
- hydrocarbon-oxy group include an alkoxy group (al Alkyloxy), alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkyl-alkyl-oxy, etc .; aliphatic hydrocarbon-oxy; aryloxy; aralkyl-oxy; alkylene And a dioxy group.
- alkoxy group examples include, for example, methoxy, ethoxy, n -propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentynoleoxy, isopentyl Noreoxy, 2-methylbutoxy, 1-methylbutoxy, neopentyloxy, 1,2-dimethylpropoxy, 1-ethynolepropoxy, n-hexinoleoxy, 4-methylinolepentoxy, 3-methylpentyl , 2-methylpentyloxy, 1-methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethylbutoxy, 1,1 dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylpropyl Toxic, 2,3-dimethylbutoxy, 2-ethylbutoxy, 1-ethylbutoxy, 1-ethyl-1-1-methylpropo Xy, n-hept
- alkenyloxy group examples include, but are not limited to, buloxy, (propenyl-1-yl) oxy, aryloxy, isopropenyloxy, (buter-1-en-yl), (buta_2-en) 1-yl) Aki-shi, (Butter 3--11-yl) Oxy-, (2-methylprop-2-yl--11-yl) Oxy, (1-methyl-propanol.
- alkynyloxy group examples include, for example, ethuroxy, (prop-1-yn-1-yl) oxy, (prop-2-yn-1-yl) oxy, and (pter-1-in-11) ⁇ f le) Okishi, (Buta 3-in-one 1 one I Lumpur) Okishi, (1 one Mechirupuro Roh, 0 - 2-in-one 1-Inore) Okishi, (penta 1-Ichi Inn one 1 one ⁇ i JV) Okishi , (Enter 4 1 in 1 1 1 yl) oxy, (hex 1 1 in 1 1 1 yl) oxy, (hex 1 5-1 in 1 1 yl) oxy, (hepter 1 1 ⁇ ⁇ (1-11) oxy, (Hepter 6—1 in 1) 1 year old, (1 octa 1 1 in 1 1) year old kiss, (1 octa 7 1 ⁇ 1 1) )) ⁇ ⁇ (, ⁇ ⁇ ⁇ (,
- Cycloalkyl one Okishi group for example, cyclopropyl Provo alkoxy, Shikurobu butoxy, cyclopentyloxy Honoré oxy, Puchiruokishi to consequent opening Kishinoreokishi, the consequent opening, cycloalkyl Otachi Ruo carboxymethyl cycloalkyl one C 3 -C 8, such as Okishi Groups.
- cycloalkyl-alkyloxy group examples include, for example, cyclopropylmethoxy, 1-cyclopropylethoxy, 2-cyclopropinoleethoxy, 3-cyclopropylpropoxy, 4-cyclopropylbutoxy, 5-cyclopropylpen Tinoleoxy, 6-cyclopropyl hexynoleoxy, cyclobutynolemethoxy, cyclopent pent / remethoxy, cyclobutynolemethoxy, cyclopentynolemethoxy, cyclohexynolemethoxy, 2-cyclohexyl / reethoxy, 3-cyclohexylpropoxy, 4-cyclo to Kishirubutokishi, cycloheteroalkyl Puchinoreme butoxy, cyclopropyl O lipped Honoré main butoxy, 6- Shikurookuchiru into C 4 -C 1 4 such Kishiruokishi Shikur
- the "Ariruokishi group”, for example, phenoxy, 1 one Nafuchiruokishi, 2 one Nafuchiruokishi, Antoriruokishi, off Henin tolyl O carboxymethyl include Ariruokishi group C e C i 4 such Asenafuchire two Ruokishi.
- aralkyloxy group examples include, for example, benzyloxy, 1-naphthylmethoxy, 2-naphthylmethoxy, anthracenylmethoxy, phenanthrenylmethoxy, acenaphthylenylmethoxy, diphenylmethoxy, 1-phenyloxy, 2-phenyloxy.
- alkylenedioxy group examples include groups such as methylenedioxy, ethylenedioxy, 1-methylmethylenedioxy, and 1,1-dimethylmethylenedioxy.
- halogenated alkoxy group examples include groups in which a hydrogen atom of a “hydroxyl group” has been replaced by a “halogenated alkyl group”.
- Nonafu Ruorobutokishi include one to one to three linear or branched C port Gen alkoxy group C ⁇ C theta substituted with a halogen atom such as a Kishiruokishi to Pafuruo port Can be
- heterocyclic oxy group a group in which a hydrogen atom of the “hydroxy group” is substituted with the “heterocyclic group” can be mentioned.
- heterocyclic group the same group as the above “heterocyclic group” Is mentioned.
- heterocyclic monooxy group for example, a monocyclic heteroaryloxy group, a condensed polycyclic heteroaryloxy group, a monocyclic non-aromatic heterocyclic oxy group, a condensed polycyclic non-oxy group And aromatic heterocyclic groups.
- Examples of the “monocyclic heteroaryloxy group” include, for example, 3-chenyloxy, (isoxazole 3-yl), (thiazole 41-yl), 2-pyridyloxy, 3-pyridyloxy, And groups such as 4-pyridyloxy and (pyrimidine-1-yl) oxy.
- Examples of the "condensed polycyclic heteroaryloxy group” include groups such as 5-indoloxy, (benzimidazole-2-yl) oxy, 2-quinolyloxy, 3-quinolyloxy, and 4-quinolyloxy.
- Examples of the “monocyclic non-aromatic heterocyclic monooxy group” include groups such as 3-pyrrolidinyloxy and 4-piperidinyloxy.
- Examples of the “condensed polycyclic non-aromatic heterocyclic monooxy group” include groups such as 3-indolinyloxy and 4-chromanyloxy.
- hydrocarbon-sulfanyl group examples include a group in which a hydrogen atom of the “sulfanyl group” is replaced by a “hydrocarbon group”.
- hydrocarbon the same as the above “hydrocarbon group” Groups.
- hydrocarbon-sulfanyl group examples include, for example, fatty acids such as an alkyl-sulfanyl group, an alkenyl-sulfanyl group, an alkynyl-sulfanyl group, a cycloalkyl-sulfanyl group, and a cycloalkyl-alkyl-sulfanyl group.
- alkyl-sulfanyl group examples include, for example, methylsulfanyl, ethylsulfaninole, n -propylsulfanyl, isopropinolesnorephaninole, n_butylsulfaninole, isobutylsnolefaninole, sec-butylinolephaninole, sec-butylinolefaninole, tert-butylinolephaninole, n-pentinoresinolenov, isopentylsnolefaninole, (2-methylbutyl) sulfanyl, (1-methinolebutinole) sulfaninole, neopentylsulfinyl, neopentylsulfinyl, (1,2-Dimethylpropyl) sulfanyl, (1-Ethynolepropynole) Snore
- alkenylsulfanyl group examples include, for example, vinylsulfanyl, (propan-1-yl) s / refaninole, arylsnolephane-norre, isopropenylsulfanyl, (butanol-en) 1-yl) Sulfanyl, (buta 1-yl) 1-sulfaninole, (buta 3-en-1 1-yl) Snolefanil, (2-methinoleprop-2-ene-1-inole) Snolefanil, (1-Methinore Proper 2-N-1-1) Snore-Faninore, (Penta-1-1-Innole) Sunore-Faninore, (Penta_2-One_1-Innole) Sunore-Faninore, (Penta-3-N) One 1-Innole) Snore Faninole, (Penter 4 _______ 1-yl) Sulfael, (3-Mechino
- alkynyl-sulfanyl group examples include, for example, ethynyl-sulfanyl, Rono. 1 1-in-1 1-in-nore) Sno-le-fani / re, (proper 2-in-1-in-no-re) Sno-le-faninole, (Butter 1-in-1-in-no-le) Sno-le-faninole, (Butter 3-in-1-1-yl) Sulfanyl, (1-methyl) Proper 2-In-1) Sulfanyl, (Penta_1-In-1), Snorefaninole, (Penter 4-In-1), Sunorefa-Nore, (Hexa-1-1) Snolephanil, (Hexar 5-in-1-yl) Snolephanil, (Hepta-1-in-1-yl), (Hepter 6-in-1-yl) Sulfanil, (Ottata 1-1-in-1) Le) Sulfanyl, (Octa 7-
- cycloalkyl-sulfanyl group examples include, for example, c-cyclopropylsulfaninole, cyclobutylsulfanyl, cyclopentinolenolephanyl, cyclohexinolesnolephanyl, cycloheptylsnolephanyl, cyclooctylsulfanyl, etc.
- cycloalkynyl Ruth Alpha alkenyl groups 3 to c 8 are exemplified.
- cycloalkyl-alkyl-sulfanyl group examples include (cyclopropylmethyl) sulfanyl, (1-cyclopropylethyl) sulfanyl, (2-cyclopropylethyl) sulfanyl, (3-cyclopropylpropyl) sulfanyl, ( 4-cyclopropylbutyl) sulfanyl, (5-cyclopropylpentyl) sulfanyl, (6-cyclopropylhexyl) sulfanyl, (cyclobutyi) (Methyl) sulfa-yl, (cyclopentylmethyl) sulfa-yl, (cyclopentinolemethyl) snorephanil, (cyclopentinolemethyl) sulfa-yl, (cyclohexylmethyl) sulfael, (2-cyclohexylethyl) sulfanyl,
- arylsulfanyl group examples include, for example, phenylsulfur-l, 1-naphthinolesulfanol, 2-naphthylsulfur-l, anthrinoles-no-refael, phenanthrino-lesulfan-n-ole, acenatfyl-noreth / refaninole And C 6 -C 14 arylsulfanyl groups.
- aralkylsulfanyl group examples include, for example, benzylsulfanyl, (1 -naphthylmethyl) sulfanyl, (2-naphthylmethyl) sulfanyl, (anthracenylmethyl) sulfur-yl, (phenanthrenylmethyl) sulfanyl, ( A senaphthyreninolemethyl) sulfanyl, (dipheninolemethinole) snorephanil, (1 phenetinole) snorefanil, (2-phenetinole) sulfanil, (1-1 (one naphthyl) ethyl) sulfanil, (1— (2 —Naphthyl) ethyl) Sulfanyl,
- the “halogenated alkyl-sulfanyl group” includes the hydrogen atom of the “sulfur group”. And a group in which the substituent is substituted with a “halogenated alkyl group”, for example, (fluoromethyl) sulfanyl, (chloromethyl) sulfanyl, (bromomethyl) sulfanyl, (odomethyl) sulfanyl, (difluoromethyl) sulfanyl, ( Trifluoromethinole) sulfanyl, (trichloromethyl) sulfanyl, (2,2,2-trifluoroethyl) sunorephanil, (pentafluoroethylenole) sulfanyl,
- heterocyclic monosulfanyl group examples include a group in which a hydrogen atom of the “sulfanyl group” is substituted with a “heterocyclic group”.
- heterocyclic ring the same as the above “heterocyclic group” Groups.
- heterocycle-sulfanyl group examples include a monocyclic heteroarylsulfanyl group, a condensed polycyclic heteroarylsulfanyl group, a monocyclic non-aromatic heterocyclic monosulfanyl group, a condensed polycyclic group A non-aromatic heterocycle-sulfanyl group;
- Examples of the “monocyclic heteroarylsulfanyl group” include, for example, (imidazole-2-yl) sulfanyl, (1,2,4-triazole-2-yl) sulfanyl, (pyridin-1-yl) sulfanyl, And groups such as (pyridine-14yl) sulfanyl and (pyrimidin-2-yl) sulfanyl.
- fused polycyclic heteroarylsulfanyl group examples include groups such as (benzimidazole-2-yl) sulfanyl, (quinoline-1-yl) sulfanyl, and (quinoline-14-inole) sulfaninole.
- Examples of the “monocyclic non-aromatic heterocyclic-sulfuryl group” include groups such as (3-pyrrolidinyl) sulfuryl and (4-piperidinyl) sulfanyl.
- Examples of the “condensed polycyclic non-aromatic heterocyclic-sulfanyl group” include groups such as (3-indole) sulfanyl and (4-chromayl) sulfuryl.
- Examples of the "acyl group” include a formyl group, a dalioxyloyl group, a thiol allyl group, a carbamoyl group, a thiocarpamoyl group, a sulfamoyl group, a sulfinamoyl group, a carboxy group, a sulfo group, a forceforno group, and the following formula: :
- a group in which R al is a hydrocarbon group is referred to as a “hydrocarbon-carbonyl group” (specific examples: acetyl, propionyl, butyryl, isobutyryl, norrelyl, isopallerinole, and vivaloy) /, Lauroyl, Millis Toinole, Palmi Toinole, Atari Loinole, Propioloinole, Methacryloinole, Crotonyl, Isocrotonyl, Cyclohexanolinyl ponyl, Cyclohexinolemethylcanolebonyl, Benzyl, 2-naphthoyl, 2-naphthoyl
- a group in which R al is a heterocyclic group is referred to as a "heterocyclic monocarbyl group” (specific examples: a group such as 2-thenoyl, 3-fluoro, nicotinol, is
- a group in which R al is a hydrocarbon group is referred to as a “hydrocarbon alkoxycarbonyl” (specific examples: methoxycarbonyl, ethoxycarbonyl, phenoxycarbonyl, Groups in which R a1 is a heterocyclic group are referred to as “heterocyclic carbonyl-carbonyl groups” (specific examples: groups such as 3-pyridyloxycarbonyl).
- a group in which R al is a hydrocarbon group is referred to as a “hydrocarbon-carboxyl-carbol group” (a specific example: a group such as pyruvoyl), and R al is A group that is a terrorist ring group is referred to as a “heterocyclic monocarbonyl group”.
- a group in which R al is a hydrocarbon group is referred to as a “hydrocarbon-oxyl-propanol-rucarponyl group” (specific examples: groups such as methoxalyl and ethoxyl).
- a group in which R al is a heterocyclic group is referred to as a “heterocyclic mono-carboxy-carbonyl group”.
- a group in which R al is a hydrocarbon group is a “hydrocarbon-sulfa-e-carponyl group”, and a group in which R al is a heterocyclic group is a “heterocyclic group”.
- -Sulfanyl-carbonyl group ".
- a group in which R a1 is a hydrocarbon group is referred to as a “hydrocarbon-thiocarbonyl group”
- a group in which R al is a heterocyclic group is referred to as a “heterocyclic-thiocarbonyl”.
- a group in which R al is a hydrocarbon group is a “hydrocarbon oxy-carbonyl group”
- a group in which R a1 is a heterocyclic group is a “hetero ring Oxythiocarponyl group ".
- a group in which R a1 is a hydrocarbon group is a “hydrocarbon-sulfanyl-thiocarbonyl group”, and a group in which R al is a heterocyclic group is a “heterocyclic group”.
- R al is a heterocyclic group
- heterocyclic group is a “heterocyclic group”.
- N-hydrocarbon-carpamoyl groups groups in which R a1 is a hydrocarbon group are referred to as “N-hydrocarbon-carpamoyl groups” (specific examples: groups such as N-methylcarbamoyl), and R A group in which al is a heterocyclic group is referred to as an “N-heterocyclic monorubumoyl group”.
- a group in which R a1 and R bl are a hydrocarbon group is referred to as “ ⁇ , ⁇ -di (hydrocarbon) one-pot rubamoyl group” (specific examples: ⁇ , A group such as bl- dimethylcarbamoinole), a group in which R al and R bl are heterocyclic groups are referred to as “N, N-di (heterocycle) one-piece rubamoyl groups”, and a group in which R al is a hydrocarbon group and R A group in which bl is a heterocyclic group is referred to as an “N-hydrocarbon-N-heterocyclic monosubstituted carpamoyl group”, and R al and R bl together form a cyclic amino group together with the nitrogen atom to which they are bonded.
- the group that is the group is referred to as a “cyclic amino-force luponyl group” (specific examples:
- a group in which R al is a hydrocarbon group is an “N-hydrocarbon-thiocarbamoyl group”, and a group in which R al is a heterocyclic group is “N-hetero group”. Ring-carbamoyl group ".
- a group R a 1 and R b 1 is a hydrocarbon group "N, N-di (hydrocarbon) - Chio force Rubamoiru group”
- R al ⁇ Pi R 3 ⁇ 41 to take group is heterocyclic group "N, N-di (heterocyclic) Single Chiokarubamoiru group”
- the group R al is a hydrocarbon radical der Ri heterocyclic group Rbl to the "N —Hydrocarbon-N-heterocyclic-thiocarbamoyl group ”
- R al and R bl together form a ring with the nitrogen atom to which they are attached.
- the group which is a amino group is referred to as "cyclic amino-thiocarbo group”.
- a group in which R al is a hydrocarbon group is “N_hydrocarbon-sulfamoyl group”, and a group in which R al is a heterocyclic group is “N-hetero group”. Ring-sulfamoyl group ".
- groups in which R a1 and! ⁇ 1 are hydrocarbon groups are referred to as “N, N-di (hydrocarbon) -sulfamoyl groups” (specific examples: N, Groups such as N-dimethylsulfamoyl), R al and R bl are heterocyclic groups as “N, N-di (heterocycle) sulfamoyl groups”, and R al is a hydrocarbon group and R A group in which bl is a heterocyclic group is an “N—hydrocarbon—N heterocyclic—sulfamoyl group”, R a1 and R bl together form a cyclic amino group together with the nitrogen atom to which they are attached.
- cyclic aminosulfuryl groups specifically examples: groups such as 1-pyrrolylsulfonyl.
- a group in which R al is a hydrocarbon group is an “N-hydrocarbon-sulfinamoyl group”
- a group in which R al is a heterocyclic group is an “N-heterocyclic group”. Sulfinamoyl group ".
- R al and R bl are hydrocarbon groups
- R al and R bl the group is a heterocyclic group but to "N, N- di (heterocyclic) Single Surufuinamoiru group”
- the group R al is a heterocyclic group is a hydrocarbon group der Ri Rbl "N- hydrocarbons one N
- a telocyclic monosulfinamoyl group, R al and R 1 together form a cyclic amino group together with the nitrogen atom to which they are attached is referred to as a “cyclic amino-sulfinyl group”.
- a group in which R al is a hydrocarbon group is a “hydrocarbon-oxysulfonyl group”, and a group in which R al is a heterocyclic group is a “heterocyclic-oxy group”. This is referred to as a “sulfoninole group”.
- a group in which R al is a hydrocarbon group is a “hydrocarbon monosulfide group”, and a group in which R al is a heterocyclic group is “heterocyclic group”. This is referred to as “oxysinorefininole group”.
- a group in which R al is a hydrocarbon group is referred to as a “hydrocarbon—snorefoninole group” (specific examples: groups such as methanesulfonyl and benzenesulfonyl) ), that the group is a heterocyclic group is R al referred to as "heterocyclic over sul Four group”.
- a group in which R a1 is a hydrocarbon group is referred to as a “hydrocarbon-sulfiel group”.
- groups such as methylsulfinyl and benzenesulfinyl
- heterocyclic monosulfinyl group A group in which R a1 is a heterocyclic group is referred to as “heterocyclic monosulfinyl group”.
- Examples of the “hydrocarbon” in the groups represented by the above formulas (co-lA) to ( ⁇ _21 ⁇ ) include the same groups as the above “hydrocarbon group”.
- the “hydrocarbon-carboxy group” represented by the formula (c—1A) includes an alkyl monocarbonyl group, an alkenyl-carbonyl group, an alkynyl-carbonyl group, a cycloalkyl monocarbonyl group, Aliphatic hydrocarbons such as cycloanole keninolecanolepo-reno group, cycloalkane gel-carbonole group, cycloalkyl-alkyl-monopropyl group, arylcarbonyl group; aralkyl-carbonyl group A crosslinked cyclic hydrocarbon monocyclic group; a spirocyclic hydrocarbon monocarbon group; a terpene hydrocarbon monocyclic group.
- the same groups as the above “heterocycle” can be mentioned.
- the “heterocyclic monophenyl carbonyl group” represented by the formula ( ⁇ -1A) includes, for example, a monocyclic heteroarylcarbonyl group, a condensed polycyclic heteroarylcarbonyl group, and a monocyclic non-aromatic.
- a heterocyclic ring group and a fused polycyclic non-aromatic heterocyclic group are examples of the “cyclic amino” in the groups represented by the above formulas (cu-lOA) to ( ⁇ -16) include the same groups as the above-mentioned “cyclic amino group”.
- a functional group when referred to as "optionally having a substituent", one or two of the functional groups may be located at a chemically possible position unless otherwise specified. Means that it may have more than one "substituent”.
- the type of substituents, the number of substituents, and the position of the substituents in the functional group are not particularly limited. When two or more substituents are present, they may be the same or different.
- Examples of the “substituent” present in the functional group include a halogen atom, an oxo group, a thioxo group, a nitro group, a nitroso group, a cyano group, an isocyano group, a cyanate group, a thiocyanato group, an isocyanato group, an isothiocyanato group, and a hydroxy group.
- Sulfanyl group carboxy group, sulfanylcarbonyl group, oxa mouth group, mesoxolo group, thiocarboxy group, dithiocarboxy group, carbamoyl group, thiocarbamoyl group, one sulfo group, sulfamoyl group, sulfino group, sulfinamoyl group, sulfinomoyl group Group, Snorrefhenamoinole group, Forceforno group, Hydroxyforceforbinole group, Hydrocarbon group, Heterocyclic group, Hydrocarbon monooxy group, Heterocyclic monooxy group, Hydrocarbon monosulfanyl group, Hetero ring A monosulfanyl group, Silyl, amino, hydrazino, hydrazono, diazenyl, ureido, thioureido, guanidino, carbamoimidoyl (amidino), carb
- a formula group may be formed.
- Such a cyclic group contains, as atoms (ring atoms) constituting a ring system, one or more heteroatoms selected from oxygen, sulfur, nitrogen and the like. May have one or more substituents on the ring. You may.
- the ring may be monocyclic or fused polycyclic and may be aromatic or non-aromatic.
- “Substituent” in the above definition of “optionally having a substituent” may be substituted by the above “substituent” at a chemically feasible position on the substituent.
- the type of the substituent, the number of the substituents, and the position of the substituent are not particularly limited. When two or more substituents are substituted, they may be the same or different.
- Such examples include, for example, an alkyl halide monoalkyl group (specific examples: groups such as trifluoroacetyl), a nodogenated alkyl-sulfonyl group (specific examples: groups such as trifluoromethanesulfonyl), an acyloxy group, Acyl-sulfanyl group, N-hydrocarbon-amino group, N, N-di (hydrocarbon) -amino group, N-heterocyclic-amino group, N-hydrocarbon-1-N-heterocyclic-amino group, acryl-amino group, Di (acyl) groups such as a monoamino group. Further, the “substitution” on the “substituent” may be repeated a plurality of times.
- acyloxy group examples include a group in which a hydrogen atom of the “hydroxy group” has been replaced by an “acyl group”.
- acyl group examples include a group in which a hydrogen atom of the “hydroxy group” has been replaced by an “acyl group”.
- ⁇ and ⁇ are the same or different and each represents a hydrocarbon group or a heterocyclic group, or R a 2 and R b 2 are bonded together. And a cyclic amino group together with the nitrogen atom).
- acyloxy group In the above definition of "acyloxy group", in the group represented by the formula ( ⁇ -IB), a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon-low-l-hydroxyloxy group” (specific examples: groups such as acetoxy and benzoyloxy), and R a2 is A group that is a heterocyclic group is referred to as a “heterocyclic 1-carbonyloxy group”.
- a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon-oxy-carboxy-l-oxy group”, and a group in which R a2 is a heterocyclic group is referred to as “ It is referred to as a "heterocyclic 1-carboxy-2-oxy group.”
- a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon radical”, a group in which R a2 is a heterocyclic group. Is referred to as a "heterocyclic group.”
- a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon-1-sulfanyl-carboxy-roxy group”, and a group in which R a2 is a heterocyclic group is referred to as “heterocyclic group”.
- Ring-sulfanyl-carbonyl group ".
- a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon-thiocarboxy-roxy group”, and a group in which R a2 is a heterocyclic group is referred to as a “heterocycle”. It is referred to as “one thiocarbonyl group”.
- a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon-oxy-carboxyl-oxy group”, and a group in which R a2 is a heterocyclic group is referred to as “ Heterocycle —oxyxycarbo-rouoxy group ”.
- a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon-snorefanyl-thiocarbo-rouoxy group”, and a group in which R a2 is a heterocyclic group is referred to as “ Heterocycle-Sulfanyl-Chomo-Rupo-Ruoxy Group ".
- R a2 and R b2 are hydrocarbon groups are referred to as “ ⁇ , ⁇ -di (hydrocarbon) one-piece rubamoyloxy group”, and R a2 and R b2 to the groups that are heterocyclic group "N, N-di (heterocyclic) Ichiriki Luba moil over O alkoxy group”, R a2 is hydrocarbon group heterocyclic group R b 2 is based on it "N- hydrocarbon - heterocycle N- - force Luba Moiruokishi group”, R a2 and R b2 are together a connexion, which is a cyclic amino group group together with the nitrogen atom to which they are attached " It is referred to as "cyclic amino-carbonyl dioxy group”.
- a group in which R a2 is a hydrocarbon group is referred to as an “N_ hydrocarbon-thiocarbamoyloxy group”, and a group in which R a2 is a heterocyclic group. Is referred to as an “N-heterocyclic monothiocarbamoyloxy group”.
- R a 2 and R b 2 is a heterocyclic group in which group the "N, N-di (heterocyclic) Single Chio force Luba moil over O alkoxy group",
- R a2 is a hydrocarbon group
- R b 2 The group that is a heterocyclic group is called “N-hydrocarbon-N-heterocycle—thiol-bamoyloxy group”, and Ra 2 and R b2 are joined together to form a nitrogen atom to which they are bonded.
- the group which is a cyclic amino group together with is referred to as "cyclic amino-thiocarbonyl-oxy group”.
- a group in which R a2 is a hydrocarbon group is referred to as “N-hydrocarbon-sulfamoyl-oxy group”, and a group in which R a2 is a heterocyclic group is referred to as “N —Heterocyclic monosulfamoyloxy group ”.
- R a 2 and R b 2 are hydrocarbon groups
- R a 2 ⁇ Pi R b 2 to the hetero ring group is a group "N, N-di (heterocyclic) Surufamoiru one Okishi group” heterocycle
- R a2 is the is R b 2 charcoal hydrocarbon group
- the group is an “N-hydrocarbon-1-N-heterocyclic sulfamoyloxy group”, and R a2 and R b2 together form a cyclic amino group together with the nitrogen atom to which they are attached.
- cyclic amino-sulfonyloxy groups are referred to as "cyclic amino-sulfonyloxy groups.”
- a group in which R a2 is a hydrocarbon group is a “N-hydrocarbon-sulfinamoyloxy group”
- a group in which R a2 is a heterocyclic group is referred to as “N-heterocyclic monosulfinamoyloxy group”.
- R a2 and R b2 are hydrocarbon groups are referred to as “ ⁇ , ⁇ -di (hydrocarbon) -sulfinamoyloxy group”, R a 2 and R a 3 ⁇ 4 2 is a heterocyclic group group is "N, N-di (heterocyclic) Single Surufuinamoiru one Okishi group”, R a2 is a hydrocarbon group R b 2 is a heterocyclic group based on the "N- hydrocarbon - heterocyclic one sulphates Inamo yl over O dimethylvinylsiloxy groups to N-”, R a2 and R b2 are together a connexion, which is a cyclic amino group group together with the nitrogen atom to which they are attached It is referred to as "cyclic amino-sulfinyloxy group”.
- a group in which R a2 is a hydrocarbon group is a “hydrocarbon mono-sulfo-roxy group”, and a group in which R a2 is a heterocyclic group is “hetero group”. Ring-oxysulfonyloxy group ".
- R a2 is a hydrocarbon group a is based on the "hydrocarbon over O key sheath sulfide two Ruokishi group", "heteroaryl groups are heterocyclic group R a2 are the Ring—oxysulfinyloxy group ”.
- R a2 and R b2 are hydrocarbon groups are referred to as “0, ⁇ , di (hydrocarbon) mono-force phonoxy group”, and R groups in which a 2 and R b 2 are heterocyclic groups are “ ⁇ , 0, —di (heterocyclic) mono-force phonoxy groups”, R a2 is a hydrocarbon group, and R b2 is a heterocyclic group Is referred to as a “ ⁇ -hydrocarbon-substituted 1-O′-heterocyclic-substituted-force-foroxy group”.
- a group in which R a2 is a hydrocarbon group is referred to as a “hydrocarbon-sulfonyloxy group”, and a group in which R a2 is a heterocyclic group is referred to as a “heterocyclic group”.
- Sulfonyloxy group ".
- a group in which R a2 is a hydrocarbon group is referred to as “hydrocarbon-sulfinyloxy group”
- a group in which R a2 is a heterocyclic group is referred to as “ Heterocyclic monosulfinyloxy group ".
- Examples of the “hydrocarbon” in the groups represented by the above formulas ( ⁇ -IB) to (o) -21 B) include the same groups as the above “hydrocarbon group”.
- the “hydrocarbon-carboenoleoxy group” represented by the formula ( ⁇ -1B) includes an alkyl-carbonyl-oxy group, an anolecenyl-one-pot oleponinoleoxy group, and an alkynyl-canoleponinole Aliphatic hydrocarbons such as an oxy group, a cycloalkyl monoalkyl group, a cycloalkenyl alkyl group, a cycloalkenyl alkyl group, a cycloalkylalkyl alkyl group, etc.
- Examples of the “heterocycle” in the groups represented by the above formulas ( ⁇ -1B) to ( ⁇ -21B) include the same groups as the above “heterocyclic group”.
- the “heterocyclic monocarbonyl group” represented by the formula ( ⁇ -1B) for example, a monocyclic heteroarylcarbonyl group, a condensed polycyclic heteroarylcarbonyl group, a monocyclic non-aromatic group
- Examples include a heterocyclic monocyclic group and a fused polycyclic non-aromatic heterocyclic monocyclic group.
- Examples of the “cyclic amino” in the groups represented by the above formulas ( ⁇ -10B) to ( ⁇ -16B) include the same groups as the above “cyclic amino group”.
- acyloxy group “hydrocarbon-oxy group”, and “heterocyclic monooxy group” are collectively referred to as “substituted oxy group”. Further, these “substituted oxy group” and “hydroxy group” are collectively referred to as “optionally substituted hydroxy group”.
- acyl-sulfanyl group examples include a group in which a hydrogen atom of the “sulfa-nore group” is substituted with an “acyl group”.
- acyl group examples include a formylsulfanyl group, a darioxyloylsulfanyl group, a thioformylsulfur- Group, carbamoyls olefaninole group, thiocanolebamoinorelesnolephanyl group, sulfamoylsulfanyl group, sulfinamoyl sulfal group, carboxysulfanyl group, sulfo Sulfanyl group, force phonosulfur group, and the following formula: s
- R a3 and R 3 are the same or different and each represent a hydrocarbon group which may have a substituent; or represents a heterocyclic group which may have a substituent, or R a3 and R 3 ⁇ 43 together with the nitrogen atom to which they are attached represent a cyclic amino group which may have a substituent).
- a group in which R a3 is a hydrocarbon group is referred to as a “hydrocarbon-carboxy-sulfanyl group”, and a group in which R a3 is a heterocyclic group. It is referred to as "heterocyclic monocarbonyl-sulfanyl group”.
- R a3 is a hydrocarbon group
- R a3 is a heterocyclic group
- the group is referred to as a "heterocyclic oxycarbonyl sulfonyl group”.
- a group in which R a3 is a hydrocarbon group is referred to as a “hydrocarbon one-pot sulfonylcarbonyl-sulfanyl group”, and a group in which R a3 is a heterocyclic group is referred to as “ Heterocyclic monocyclic carbonyl-sulfanyl group ".
- R a3 is a hydrocarbon group a is based on the "hydrocarbon one Okishi one Kanorepo two Norre one Kanorepo - Rusurufa two / Les group”
- R a 3 is the The group that is a terrorist ring group is referred to as a “heterocyclic mono-l-carbonyl-carboxy-l-sulfanyl group”.
- a group in which R a3 is a hydrocarbon group is referred to as a “hydrocarbon-sulfur-loop-lponyl-sulfanyl group”
- R a3 is a heterocyclic group.
- the group is referred to as a "heterocycle-l-sulfanyl-carboxyl-sulfanyl group”.
- a group in which R a3 is a hydrocarbon group is a “hydrocarbon-thiocarboylsulfur group”, and a group in which R a3 is a heterocyclic group. It is referred to as "heterocyclic-l-carboxy-l-sulfanyl group”.
- the group R a 3 is a hydrocarbon group "hydrocarbon one Okishi one Chiokarupo two loose Alpha group", to the R a 3
- the group is referred to as a "heterocyclic 1-oxo-carboxyl-sulfanyl group”.
- a group in which Ra 3 is a hydrocarbon group is referred to as a “hydrocarbon-1-sulfa-lucio-carbo-2-sulfur-aryl group”, and Ra 3 is a heterocyclic group.
- Certain groups are referred to as "heterocyclic-sulfanyl-thiocarbo-rusulfanyl groups”.
- a group in which R a3 is a hydrocarbon group is referred to as an “N-hydrocarbon monofunctional rubamoyl-sulfanyl group”, and a group in which R a3 is a heterocyclic group.
- Certain groups are referred to as "N-heterocyclic ring-carbamoyl-sulfanyl groups”.
- R a3 and R b3 are hydrocarbon groups are referred to as “ ⁇ , ⁇ -di (hydrocarbon) one-piece rubamoyl-sulfanyl group”, R groups in which a3 and R b3 are heterocyclic groups are “N, N-di (heterocyclic) mono-rubbamoyl-sulfanyl groups”; groups in which Ra3 is a hydrocarbon group and Rb3 is a heterocyclic group the "N- hydrocarbon one N- ⁇ ⁇ heterocyclic Ichiriki Luba Moi Ruth Alpha group", such together R a3 and R b3 are connexion, they are cyclic Amino group together with the nitrogen atom bonded group " It is referred to as "cyclic amino mono-l-ponyl-sulfamoinole group”.
- R a3 is a hydrocarbon group a is based on the "N- hydrocarbons - Chio carbamoylthiopheno Ruth Alpha group", the group is a heterocyclic group R a3 is It is referred to as "N-heterocyclic-thiocarbamoyl-sulfanyl group”.
- R a3 and R b3 are hydrocarbon groups are referred to as “ ⁇ , ⁇ -di (hydrocarbon) —thiol-bamoyl-sulfanyl group”, R a3 and R b3 to the groups that are heterocyclic group "N, N-di (heterocyclic) Single Chio carbamoylthiopheno Ruth Alpha two Le group”, R a3 is a hydrocarbon radical R b3 to the at heterocyclic group A group is called an “N-hydrocarbon-N-heterocyclic ring-thiocarbamoyl-sulfanyl group”, and R a 3 and R b 3 are taken together to form a cyclic amino group together with the nitrogen atom to which they are bonded. Is referred to as a “cyclic aminotinyl carporinyl sulfanyl group”.
- a group in which R a3 is a hydrocarbon group is referred to as “N-hydrocarbon-sulfamoyl-sulfanyl group”, and a group in which R a3 is a heterocyclic group is referred to as “N — Heterocycle-sulfamoyl-sulfanyl group ”.
- groups in which R a 3 and 1 ⁇ 3 are hydrocarbon groups are referred to as “ ⁇ , ⁇ -di (hydrocarbon) -sulfamoyl-sulfanyl groups”, ⁇ the ⁇ Pi ⁇ Gaete port ring group in which the group "New, Nyu- di (heterocyclic) over sulfamoylcarbamoyl loose sulfinyl group”, groups R a3 is a heterocyclic group a and R b3 to a hydrocarbon group
- ⁇ —hydrocarbons A group in which R a3 and R b3 are taken together to form a cyclic amino group together with the nitrogen atom to which they are attached is referred to as a ⁇ cyclic amino-sulfo-mono-sulfanyl group '' .
- R a3 is a hydrocarbon group
- R a3 is a heterocyclic group
- the group is referred to as "N-heterocyclic monosulfinamoyl-sulfanyl group”.
- R a3 and R b3 are hydrocarbon groups are referred to as “N, N-di (hydrocarbon) -sulfinamoyl-sulfanyl groups”, R a3 And R b3 is a heterocyclic group, an “N, N-di (heterocycle) sulfinamoyl-sulfanyl group”, R a3 is a hydrocarbon group, and R b3 is a heterocyclic group.
- N-hydrocarbon-N-heterocycle-sulfinamoyl-sulfanyl group a group that is a cyclic amino group together with the nitrogen atom to which they are attached. It is referred to as “cyclic anosulfuryl sulfanyl group”.
- a group in which R a3 is a hydrocarbon group is referred to as a “hydrocarbon-oxinoleforyl-2-norephanyl group”, and a group in which R a3 is a heterocyclic group. Is referred to as a "heterocycle-l-oxy-sulfonyl-sulfanyl group”.
- a group in which R a3 is a hydrocarbon group is referred to as a “hydrocarbon group”.
- R a 3 is a hydrocarbon group a is based on the "hydrocarbon Surufo - Loose Alpha group", "heteroaryl groups are heterocyclic group is R a 3 A ring is referred to as a "synolefino-norrenophaninole group".
- the group R a 3 is a hydrocarbon group "hydrocarbon over scan Honoré Fini Ruth Alpha group” is a heterocyclic group is R a 3 group Is referred to as a "heterocyclic-sulfiel-sulfanyl group".
- hydrocarbon in the groups represented by the above formulas ( ⁇ -1 C) to ( ⁇ -21 C) include the same groups as the above “hydrocarbon group”.
- the “hydrocarbon-1-carbonylsulfanyl group” represented by the formula (1-1C) includes alkyl-carbonyl-sulfanyl group, alkenyl-carbonyl-sulfanyl group, alkynyl-carbonyl-sulfanyl group.
- Aliphatic hydrocarbons such as canoleponinole-no-refa-nore group, cycloanolequinoleanolekyle-one-oleboninole-sulfanyl group, etc.—re-n-phenyl-sulfanyl group; aryl-carbonyl-ne-sulfanyl group; Group; a crosslinked cyclic hydrocarbon-carboxylsulfanyl group; a spirocyclic hydrocarbon monopropanolsulfanyl group; a terpene hydrocarbon-carboxylsulfanyl group.
- Examples of the “heterocycle” in the groups represented by the above formulas (co-1C) to ( ⁇ -21C) include the same groups as the above “heterocyclic group”.
- examples of the “heterocyclic monophenylsulfanyl group” represented by the formula (co-1 C) include, for example, a monocyclic heteroarylcarbyl-2-sulfanyl group, a condensed polycyclic heteroarylcarbonyl group.
- Examples include a rusulfanyl group, a monocyclic non-aromatic heterocyclic monosulfol-sulfanyl group, and a condensed polycyclic non-aromatic heterocyclic monocyclic sulfonylsulfur group.
- acyl-sulfanyl group hydrocarbon monosulfanyl group
- heterocyclic monosulfanyl group heterocyclic monosulfanyl group
- N_ hydrocarbon-amino group examples include groups in which one hydrogen atom of the “amino group” has been replaced with a “hydrocarbon group”.
- an N-alkyl-amino group, an N-alkenyl group examples include an amino group, an N-alkynyl-amino group, an N-cycloalkylamino group, an N-cycloalkyl-alkyl-amino group, an N-arylamino group, and an N-aralkyl-amino group.
- N-alkylamino group examples include methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, tert-butynoleamino, n-pentylamino, isopentylamino, and (2-methylbutyl ) Amino, (1-methylbutyl) amino, neopentylamino, (1,2-dimethylpropyl) amino, (1-ethylpropyl) amino, n-hexylamino, (4-methylpentyl) amino, (3-methylpentyl) amino , (2-methylpentyl) amino, (1-methylpentyl) amino, (3,3-dimethylbutyl) amino, (2,2-dimethylbutyl) amino, (1,1-dimethylbutyl) amino, (1,2-dimethylbutyl) amino,
- N-alkyne-amino group examples include, but are not limited to, bulamino, (propanol 1-1 f) amino, butarylamino, isopropenylamino, (butter-1-enyl) amino, (buta-2- Amino, (Butter 3-11-1) Amino, (2-Methylpropane 2-1-1) Amino, (1-Methinolprop 2-1-1-Inole) Amino, (Penter 1 _ 1 -1 ⁇ inole) Amino, (Penter 2 ⁇ 1 ⁇ 1 ⁇ 1) Amino, (Penta 1 — 3 ⁇ 1 ⁇ 1 ⁇ 1) Amino, (penta-1-4-yl) Amino, (3-methylbuter-2-en-1-yl) Amino, (3-methylbuta-3-en-1-yl) Amino, (hexa-1-yl) Amino, (hex 1 2 _en 1 ill
- N-alkynyl-amino group examples include, for example, ethininoleamino, (prop-1-yn-1-yl) amino, (prop-2-yn-1-yl) amino, and (butanol-1-in-1) Amino, (Butter 3-in-1-1-yl) Amino, (1-Methinole proper 2-in-1-1-yl) Amino, (Penta-11-in-1-yl) Amino,
- N-cycloalkylamino group examples include, for example, C 3 -C 8 such as cyclopropylamino, cyclobutynoleamino, pentylamino, cyclohexylamino, cycloheptylamino, cyclooctylamino, etc. N-cycloalkynoleamino group.
- N-cycloalkyl-alkyl-amino group examples include, for example, (cyclopropynolemethinole) amino, (1-cyclopropylethyl) amino, (2-cyclopropylethyl) ⁇ amino, and (3-cyclopropylpropyl).
- N- Ariruamino group for example, Fueniruamino, 1 Nafuchirua amino, 2-Nafuchiruamino, Antoriruamino, full We phenanthryloxy ⁇ amino and N- mono- chromatography aryl ⁇ amino group C 6 -C 1 4 such Asena Fuchireniruamino No.
- N-aralkyl monoamino group examples include, for example, benzylamino, (1-naphthylmethyl) amino, (2-naphthylmethyl) amino, (anthracenylmethyl) amino, (phenanthrylmethyl) amino, ( (Acenaphthylenylmethyl) amino, (Diphenylmethyl) amino, (1-phenyl) amino, (2-phenyl) amino, (1-1-naphthyl) ethyl, (1- (2-naphthyl) ethyl), (2— (1— (Naphthyl) ethyl) amino, (2- (2-naphthyl) ethyl) amino, (3-phenylphenyl) amino, (3- (1-naphthyl) propyl) amino, (3- (2-naphthyl) propyl) Amino, (4-phenylbutyl) Amino, (4-
- N, N-di (hydrocarbon) amino group a group in which two hydrogen atoms of the “amino group” are substituted with a “hydrocarbon group” can be mentioned, for example, N, N-dimethylamino, N , N-Jetylamino, N-ethyl-N-methylamino, N, N-Di-n-propylamino, N, N-Diisopropylamino, N-Aryl N-Methylamino, N— (Proper-2-in-1 1-yl) 1-N-methylamino, N, N-dicyclohexinoleamino, N-cyclohexyl-1-N-methylamino, N-cyclohexynolemethylamino-N-methylamino, N, N-diphenylamino, N-methyl-1
- Examples include groups such as N-phenylamino, N, N-dibenzylamino, N-benzyl-
- N-heterocyclic-amino group examples include groups in which one hydrogen atom of the “amino group” has been substituted with a “heterocyclic group”.
- N-hydrocarbon_N-heterocyclic monoamino group is a group in which two hydrogen atoms of an “amino group” are substituted one by one with a “hydrocarbon group” and a “heterocyclic group”, respectively.
- N-methyl-N- (4-piperidinyl) amino, N- (4-chromanyl) examples thereof include groups such as 1-N-methylamino, N-methyl-N- (3-phenyl) amino, N-methyl-N- (3-pyridyl) amino, and N-methyl-N- (3-quinolyl) amino.
- acyl-amino group examples include groups in which one hydrogen atom of the “amino group” has been replaced with an “acyl group”.
- acyl group examples include groups in which one hydrogen atom of the “amino group” has been replaced with an “acyl group”.
- a formylamino group a glyoxyloylamino group, a thioformylamino group, Carbamoylamino group, thiocarbamoylamino group, sulfamoylamino group, sulfinamoylamino group, carboxyamino group, sulfamino group, forceforamino group, and the following formula:
- R a4 and R 3 ⁇ 44 are the same or different and each represents a hydrocarbon group which may have a substituent, or a heterocyclic group which may have a substituent, or a4 and Rb4 are taken together, and together with the nitrogen atom to which they are attached, represent a cyclic amino group which may have a substituent).
- acyl-amino group In the definition of "acyl-amino group",
- a group in which R a4 is a hydrocarbon group is referred to as a “hydrocarbon-carbonyl-amino group”, and a group in which R a4 is a heterocyclic group is referred to as “heterocycle”.
- Ring-Carponylamino group ".
- a group in which R a4 is a hydrocarbon group is referred to as a “hydrocarbonoxycarbonylamino group”, and a group in which R a4 is a heterocyclic group is referred to as “ Heterocycle-Xycarborylamino group ".
- a group in which R a4 is a hydrocarbon group is a “hydrocarbon one-pot carbonyl group”, and a group in which R a4 is a heterocyclic group. Is referred to as a "heterocyclic monocarboxycarbonyl-amino group”.
- R a4 is a hydrocarbon group
- R a4 is a heterocyclic group.
- Certain groups are referred to as "heterocycle-loxy-l-carboxylamino groups”.
- a group in which R a4 is a hydrocarbon group is referred to as a “hydrocarbon-phenylamine group”, and a group in which R a4 is a heterocyclic group is referred to as “ Heterocyclic-sulfanyl-propanol-amino group ".
- a group in which R a4 is a hydrocarbon group is referred to as a “hydrocarbon-thiocarbo-l-amino group”, and a group in which R a4 is a heterocyclic group is referred to as a “heterocyclic group”. It is referred to as "thiokarpinoruamino group”.
- a group in which R a4 is a hydrocarbon group is referred to as a “hydrocarbon hydrocarbonoxycarbonylamino group”, and a group in which R a4 is a heterocyclic group. It is referred to as "heterocycle-oxy-carbonyl-amino group”.
- a group in which R a4 is a hydrocarbon group is a “hydrocarbon-1 phenyl-thiocarbonyl-amino” group, and a group in which R a4 is a heterocyclic group. Is referred to as a "heterocycle-sulfanyl-thiocarbonyl-amino group".
- a group in which R a4 is a hydrocarbon group is referred to as an “N-hydrocarbon monovalent rubamoyl group”, and a group in which R a4 is a heterocyclic group is referred to as “N —Heterocycle—Carbamo "Ylamino group”.
- R a4 and R b4 are hydrocarbon groups are referred to as “ ⁇ , ⁇ -di (hydrocarbon) one-piece rubamoyl-amino group”, R a4 A group in which R b4 is a heterocyclic group; a group in which R a4 is a hydrocarbon group and R "is a heterocyclic group; Is referred to as an “N-hydrocarbon-N-heterocyclic monovalent rubamoyl-amino group”, R a4 and R b4 are united to form a cyclic amino group together with the nitrogen atom to which they are bonded. It is referred to as a "ruamino group.”
- a group in which R a4 is a hydrocarbon group is referred to as an “N-hydrocarbon monothiocarbamoyl-amino group”, and a group in which R a4 is a heterocyclic group. It is called "N-heterocyclic monothiocarbamoyl-amino group”.
- the group R a4 and R b4 are hydrocarbon groups " ⁇ , ⁇ - di (hydrocarbon) Single Chio force Rubamoiru - Amino group", R a 4 is "N, N-di (heterocyclic) Single Chio force Luba carbamoyloxy over amino group", R a4 is a hydrocarbon group heterocyclic group is R b4 the group is a heterocyclic group, and the R b 4 is The group is an “N-hydrocarbon-N-heterocyclic monothiocarbamoyl-amino group”, a group in which R a4 and R b4 together form a cyclic amino group together with the nitrogen atom to which they are attached. It is referred to as "cyclic aminoaminocarbonylamino group”.
- a group in which R a4 is a hydrocarbon group is called “N-hydrocarbon-sulfamoyl-amino group”, and a group in which R a4 is a heterocyclic group is called “N— Heterocyclic monosulfamoyl-amino group ".
- R a4 and R b4 are hydrocarbon groups, R a 4 and R 3 ⁇ 4 4 is to based on a heterocyclic group "N, N- di (heterocyclic) sulfamoylamino over amino group", R a 4 is a hydrocarbon group a and R b4 to the groups that are heterocyclic group "N- hydrocarbons - heterocycle N-- Surufamoi Ruamino group ", R a4 and R b4 are together referred to a group is a cyclic amino group together with the nitrogen atom to which they are attached a" cyclic amino chromatography sul Four two Ruamino group " I do.
- a group in which R a4 is a hydrocarbon group is referred to as an “N_hydrocarbon-sulfinamoyl-amino group”, and a group in which R a4 is a heterocyclic group. It is referred to as "N-ring-sulfinamoyl-amino group”.
- R a4 and R "are a hydrocarbon group among the groups represented by the formula ( ⁇ _16 D) are referred to as“ N, N-di (hydrocarbon) -sulfinamoyl-amino group ”, R a4 and A group in which R b4 is a heterocyclic group is referred to as an “N, N-di (heterocycle) sulfinamoyl-amino group”; a group in which R a4 is a hydrocarbon group and R b4 is a heterocyclic group is referred to as “ N- hydrocarbons one N hetero ring - sulphates Inamo yl chromatography amino group ", become R a4 and R b4 gar cord, based on the" cyclic amino is they are attached a ring-shaped amino groups together with the nitrogen atom Northulfinylamino group ".
- a group in which R a4 is a hydrocarbon group is referred to as a “hydrocarbon-oxysulfide monoamino group”, and a group in which R a4 is a heterocyclic group is referred to as “ Heterocycle 1 oxy 1 sulfide 1 amino group ".
- R a4 and R b4 are hydrocarbon groups are referred to as “0, 0, di- (hydrocarbon) mono-force for amino group”, R a4 and A group in which the length 134 is a heterocyclic group is a “0,0, di (heterocyclic) mono-force for amino group”, R a4 is a hydrocarbon group, and R b4 is a heterocyclic group.
- the group is referred to as "0-hydrocarbon-O '- ⁇ , ⁇ mouth ring-force-for-amino group”.
- R a 4 is a hydrocarbon group a is based on the "hydrocarbon Surufo sulfonyl one Amino group", “heteroaryl groups are heterocyclic group R a4 is the A ring-sulfonyl-amino group ".
- a group in which R a4 is a hydrocarbon group is referred to as a “hydrocarbon-sulfuryl-amino group”, and a group in which R a4 is a heterocyclic group is referred to as a “heterocycle-sulfo group.
- Examples of the “hydrocarbon” in the groups represented by the above formulas (CD-ID) to (o-21D) include the same groups as the above “hydrocarbon group”.
- hydrocarbon-carbo-amino group represented by the formula ( ⁇ -l D) includes an alkyl-carbonyl-amino group, an alkenyl-carboxy-amino group, an alk-carbonyl-amino group, and a cycloalkyl-amino group.
- Aliphatic hydrocarbons such as carpyl monoamino group, cycloalkenyl radical amino group, cycloalkenylenyl-carboxy amino group, cycloalkyl alkyl monopropyl amino group, etc .; arylcarbyl amino group; arylcarbyl amino group An aralkyl-carboxyamino group; a crosslinked cyclic hydrocarbon monopropylamino group; a spirocyclic hydrocarbon monocarboxyamino group; a terpene hydrocarbon monopropylamino group.
- Examples of the “heterocycle” in the groups represented by the above formulas ( ⁇ -1D) to ( ⁇ -21D) include the same groups as the above “heterocyclic group”.
- the “heterocyclic monopropylamino group” represented by the formula (1-1D) includes, for example, a monocyclic heterocarboxylamino group and a condensed polycyclic heteroarylcarbo group.
- Examples include a 2-amino group, a monocyclic non-aromatic heterocyclic monocyclic amino group, and a condensed polycyclic non-aromatic heterocyclic monocyclic amino group.
- Examples of the “cyclic amino” in the groups represented by the above formulas ( ⁇ -10 D) to (co-16 D) include the same groups as the above “cyclic amino group”.
- di (fallyl) -amino group di (dalioxylol) -amino group, di (thiophenolyl) -amino group, di (lvamoyl) amino group, di (thiolrubamoyl) ) -Amino group, di (sulfamoyl) monoamino group, di (sulfinamoyl) monoamino group, di (force ⁇ / boxy) monoamino group, di (sulfo) amino group, di (force phono) amino group, and The following formula: 0307127
- R a5 and R b5 together represent a cyclic amino group which may have a substituent together with the nitrogen atom to which they are bonded.
- a group in which Ra 5 is a hydrocarbon group is referred to as “bis (hydrocarbon group) —Carbonyl ”-amino group” and a group in which R a5 is a heterocyclic group are referred to as “bis (heterocyclic-1-carbonyl) -amino groups”.
- a group in which R a5 is a hydrocarbon group is referred to as a “bis (hydrocarbon—oxy-one-propionyl) amino group”, and a group in which R a5 is a heterocyclic group is referred to as “ Bis (heterocycle-oxyl-propionyl) -amino group ".
- a group in which R a5 is a hydrocarbon group is a “bis (hydrocarbon mono-carbonyl) amino group, and a group in which R a5 is a heterocyclic group. Is referred to as a “bis (heterocycle-carbocarbonylcarbonyl) -amino group”.
- R a5 is a hydrocarbon group
- R a5 is a heterocyclic group
- One group is referred to as a "bis (heterocycle-l-oxyl-l-ponyl-l-carbonyl) -amino group”.
- R a 5 and a group is a hydrocarbon group "bis (hydrocarbon - sulfanyl Lou carbonyl) Amino group", the group is a heterocyclic group is R a 5 It is called “bis (heterocycle-sulfanyl-carbonyl) -amino group”.
- a group in which R a5 is a hydrocarbon group is a “bis (hydrocarbon monooxycarbonyl) -amino group”, and a group in which R a5 is a heterocyclic group. Is referred to as a “bis (heterocyclic-l-oxy-l-carbonyl) -amino group”.
- a group in which R a5 is a hydrocarbon group is a “bis (hydrocarbon-sulfanyl-thiocarbonyl) -amino group”, and a group in which R a5 is a heterocyclic group.
- bis (heterocyclic monosulfanyl-thiocarbol) monoamino group A group represented by the formula (.omega. 9E), the group R a 5 is a hydrocarbon group "bis (N- hydrocarbon Ichiriki Rubamoiru) Amino group” is a heterocyclic group is R a 5 group Is referred to as a “bis (N-heterocyclic monorubumoyl) -amino group”.
- a group in which R a5 and R b5 are a hydrocarbon group is referred to as a “bis [N, N-di (hydrocarbon) Ichiriki Rubamoiru] Amino group ", R a5 ⁇ Pi R b5 Gaete port ring group in which group the" bis [N, N-di (heterocyclic) Ichiriki Rubamoiru] - Amino group ", the group R a5 is a hydrocarbon group a is heterocyclic group R 3 ⁇ 45 is to (hetero the N- hydrocarbon one N one ring - power Rubamoiru)" bis one Amino group ", R a 5 and
- the group in which R b 5 together, together with the nitrogen atom to which they are attached, is a cyclic amino group is referred to as a “bis (cyclic amino-propanol) monoamino group”.
- a group in which R a5 is a hydrocarbon group is a “bis (N-hydrocarbon-1-thiocarbamoyl) monoamino group”, and R a5 is a heterocyclic group.
- Amino group ", 1 35 ⁇ Pi 1 3 ⁇ 45 is a group or a heterocyclic group” bis [N, N-di (heterocyclic) Single Chiokarubamoiru] one Amino group ", R a 5 is a hydrocarbon group a has the R b5 to is a heterocyclic group group” bis (N_ hydrocarbon one N- heterocyclic one Chiokarubamoiru) - Amino group ", R a5 ⁇ Pi R b5
- a group that is a cyclic amino group together with the nitrogen atom to which they are attached is called a bis (cyclic amino-thiocarbonyl) monoamino group.
- groups in which R a5 and R b5 are hydrocarbon groups are referred to as “bis [N, N-di (hydrocarbon) sulfinamoyl] -amino group”, ⁇ and!
- a group in which ⁇ is a heterocyclic group is referred to as a “bis [N, N-di (heterocycle) -sulfinamoyl] -amino group”, and a group in which R a5 is a hydrocarbon group and R b5 is a heterocyclic group.
- a group in which R a5 is a hydrocarbon group is a “bis (hydrocarbon-oxysulfonyl) amino group”, and a group in which R a5 is a heterocyclic group. It is referred to as "bis (heterocyclic-oxysulfonyl) -amino group”.
- a group represented by the formula (.omega. 18E), is a heterocyclic group the group R a 5 is a hydrocarbon group "bis (hydrocarbon Motoichi O Kishi sites sulfonyl) Amino group", R a5 are the Group
- R a5 and R b5 are heterocyclic groups
- groups in which R a5 and R b5 are heterocyclic groups are referred to as“ bis [ ⁇ , ⁇ , di (heterocycle) ”monoforce groups.
- a group in which R a5 is a hydrocarbon group and R b5 is a heterocyclic group is referred to as a “bis (O 1 hydrocarbon-1o, 1 heterocycle 1 force phono) amino group”.
- R a5 is a is based on the hydrocarbon group "bis (hydrocarbons over Sul Four sulfonyl) Amino group" te the group is a heterocyclic group R a5 are the "to bis ( Ring-sulfonyl) -amino group ".
- a group in which R a5 is a hydrocarbon group is a “bis (hydrocarbon-sulfiel) -amino group”
- a group in which R a5 is a heterocyclic group is “bis (heterocyclic-sulfinyl) ) Amino group ".
- hydrocarbon in the group represented by the above formulas ( ⁇ _1 ⁇ ) to (c — 21 ⁇ ) And the same groups as the above “hydrocarbon group”.
- bis (hydrocarbon monocarbonyl) amino group represented by the formula (0-1E)
- Bis (aliphatic hydrocarbon monocarbonyl) such as —amino group, bis (cycloalkenyl-carbonyl) monoamino group, bis (cycloalkenylenyl-carbonyl) -amino group, bis (cycloalkyl-alkynole) -amino group
- Bis (aralkylcarbol) -amino group bis (aralkyl monopropyl) amino group; bis (bridged cyclic hydrocarbon monopropyl) -amino group; bis (spirocyclic hydrocarbon monocarbonyl) A) amino group; bis (terpene hydrocarbon monocarbonyl) -amino group.
- the “bis (heterocyclic monocarbonyl) amino group” represented by the formula ( ⁇ -1E) includes, for example, a bis (monocyclic heteroarylcarbonyl) amino group and a bis (condensed polycyclic heteroaryl) group. And a bis (monocyclic non-aromatic heterocyclic monocarbyl) amino group, and a bis (condensed polycyclic non-aromatic heterocyclic monocyclic ruponyl) -amino group.
- acyl-amino group and “di (acyl) amino group” are collectively referred to as “acyl-substituted amino group”.
- N-hydrocarbon-amino group N, N-di (hydrocarbon) -amino group
- N-heterocyclic monoamino group N-hydrocarbon-1-N-heterocyclic amino group
- Cyclic amino group acyl-amino group
- di (acyl) amino group are collectively referred to as” substituted amino group ".
- the “linking group having 2 to 5 main chain atoms” in the definition of X means a connecting group in which 2 to 5 main chain atoms are connected between rings Z and E.
- the above “number of atoms in the main chain” shall be counted so as to minimize the number of atoms existing between the rings Z and E regardless of the presence or absence of CHI and heteroatoms.
- 1,2-cyclopentylene has two atoms
- 1,3-cyclopentylene has three atoms
- 1,4-phenylene has four atoms
- 2,6-pyridinediyl has four atoms.
- linking group having 2 to 5 atoms in the main chain is formed of one group selected from the following “divalent group group ⁇ —1” or the following “divalent group group” It is formed by combining 2 to 4 groups of 1 to 4 selected from ⁇ —2 ”.
- each group may be the same or different.
- the above “linking group having 2 to 5 atoms in the main chain” is preferably a group selected from the following linking group ⁇ .
- the substituent of "the linking group may have a substituent” in the definition of “the linking group having 2 to 5 atoms of the main chain”, the above-mentioned “optionally having a substituent”
- the same groups as the "substituents” in the definition of “” are preferred, preferably a CiCs alkyl group, and more preferably a methyl group.
- the substituent may be taken together with the substituent on ring Z or E to form a cyclic group which may have a substituent, together with the atom to which they are bonded.
- a compound represented by the general formula (I) is represented by the following formula:
- the “replacement group” of the “optionally substituted acyl group is the above “replacement group”. May be the same as the above “substituent”.
- the position of the substituent on the acyl group is not particularly limited. When two or more substituents are present, they may be the same or different.
- the “acyl group” of the “acyl group which may have a substituent (excluding the unsubstituted acetyl group and the unsubstituted acryloyl group)” is the “acyl group” in the above definition. And the same groups as mentioned above.
- the “optionally substituted acetyl group” in the definition of A above excludes an unsubstituted acetyl group and an unsubstituted acryloyl group.
- the “optionally substituted acyl group (however, excluding an unsubstituted acetyl group and an unsubstituted acryloyl group)” is preferably the following “substituent group ⁇ And more preferably a heterocyclic monocarbyl group which may have a substituent, a force phono group which may have a substituent, and a group having a substituent. Is an optionally substituted rubamoyl group.
- Substituent group ⁇ Hydrocarbon optionally having a substituent, a monovalent luponyl group having a substituent, heterocyclic optionally having a monocyclic luponyl group, a hydrocarbon having an optional substituent A monooxycarbonyl group, a hydrocarbon monosulfol group which may have a substituent, a sulfamoyl group which may have a substituent, a sulfoyl group which may have a substituent, A force phono group which may have a group and a substituent Carpamoyl group
- the "optionally substituted acyl group” force S “optionally substituted heterocyclic-carbonyl group” is more preferably "5 to 6 Membered non-aromatic heterocyclic monovalent luponyl group, which contains at least one nitrogen atom as an atom (ring atom) constituting the hetero ring, and is bonded to the carboyl group via a nitrogen atom.
- Particularly preferred are (pyrrolidine-111-yl) carbonyl, (morpholine-141-yl) carboxy, and (4-methylbiperazine-1-1).
- the “optionally substituted acyl group” is a force S.
- the “optionally substituted force phono group” it is preferably a force phono group, and It is a dibenzylforce phono group, and more preferably a force phono group.
- the “optionally substituted acyl group” in the definition of A above is an “optionally substituted substituent group”, more preferably “N, N-disubstituted carbyl group” Bamoyl group ", and more preferably, N, N-dimethylcarbamoyl group, N, N_getylcarbamoyl group, N-methyl-N-phenylcarbamoyl group, N, N-bis [(ethoxycaponyl) Methyl] -l-bamoyl group, and ⁇ , ⁇ -bis (l-lupoxymethyl) group.
- an optionally substituted acyl group f If the term “an optionally substituted hydrocarbon or ethoxy group” refers to the "hydrocarbon group” Examples include the same groups as the “hydrocarbon group” in the above definition.
- the "optionally substituted acyl group” is a force S “optionally substituted hydrocarbon-sulfonyl group”, and the “hydrocarbon group” is as defined above.
- the same groups as the "hydrocarbon group” in the definition can be mentioned.
- the force S "optionally substituted hydrocarbon-sulfonyl group"
- a specific example of a preferable group is methane.
- a snorphorol group [mesyl group]
- a propanesulfonyl group an isopropyl pyrsulfonyl group
- a p-toluenesulfonyl group tosinole group.
- suitable groups include (pyrrolidine-111) carbonyl, (morpholine-114) carbonyl, and (4-methylbiperazine_11) Group, (4-ethoxypiperidin-1-yl) carboxyl group, (4-carboxypiperidin-1-yl) carbony
- the “substituent” of the “CiCe alkyl group optionally having a substituent” includes the “substituent” of the above “optionally having a substituent”. Similar groups may be mentioned.
- the position of the substituent on the alkyl group is not particularly limited. When two or more substituents are present, they may be the same or different.
- the ⁇ alkyl group of Ci Ce optionally having substituent (s) '' in the definition of A above is more preferably an acyloxymethylene group which may have substituent (s), and still more preferably Represents an acetooxymethyl group, a (bivaloyloxy) methyl group, a 1- (ethoxycarbonyloxy) ethyl group, a [(piperidinocarbonyl) methyl] group, a [(morpholinocaprolponyl) methyl], ( ⁇ [ 4_ (Ethoxycarbonyl) piperidine-l-yl] carbonyl ⁇ methyl) methyl group, ⁇ [(4-force lipoxypiperidine-l-yl) carbonyl] methyl ⁇ methyl group, ( ⁇ N, N —Bis [(ethoxycarbonyl) methyl] rubumoyl ⁇ methyl group and ⁇ [N, N-bis (carboxymethyl) rubumamoyl] methyl group.
- A may combine with the linking group X to form a ring structure which may have a substituent.
- preferred specific examples of the compound represented by the general formula (I) include the following formula:
- ring Z a group represented by “formula O—A (where A is as defined above) and formula X—E (where X and E are as defined above)
- examples of the “arenes” of the “arenes which may further have a substituent” include monocyclic or condensed polycyclic aromatic hydrocarbons, for example, a benzene ring, a naphthalene ring, and an anthracene ring. And a phenanthrene ring and an acenaphthylene ring.
- C 6 -C 10 arene such as a benzene ring or a naphthalene ring, more preferably a benzene ring or a naphthalene ring, and most preferably a benzene ring.
- ring Z it is represented by “Formula — 0—A (where A is as defined above) and Formula 1 X—E (where X and E are as defined above)
- the “substituent” of the “arene which may further have a substituent in addition to the above group” include the same groups as the “substituent” in the definition of the above “may have a substituent”. No.
- the substitution position of the substituent on the arene is not particularly limited. When two or more substituents are present, they may be the same or different.
- ring Z it is represented by “Formula O—A (where A is as defined above) and Formula X—E (where X and E are as defined above) Arene which may further have a substituent in addition to the group represented by the following formula: force s ⁇ Formula _ 0 — A (where A is as defined above. And a benzene ring which may further have a substituent in addition to the group represented by the formula -X-E (wherein X and E are as defined above).
- the formula is represented by “formula O—A (where A is as defined above) and formula 1; X—E (wherein X and E are as defined above) A benzene ring further having one or two substituents in addition to the group ”, and more preferably, a benzene ring having the formula: O—A (where A is as defined above) and the formula: X—E (Wherein, X and E are as defined above) and a benzene ring having one more substituent.
- the substituent is preferably a group selected from the following “substituent group ⁇ -1z”, and more preferably a halogen atom and a tert-butyl group [(1, 1 -Dimethyl) ethyl group], and most preferably a halogen atom.
- ring Z it is represented by “Formula O—A (where A is as defined above) and Formula—X—E (where X and E are as defined above) Arene which may further have a substituent in addition to the group represented by the following formulas: s "Formula 1 O—A (where A is as defined above) and Formula—X—E (wherein X and E have the same meanings as defined above), and a benzene ring which may further have a substituent in addition to the group represented by the formula (I):
- R z is preferably a group selected from the following “substituent group ⁇ - 2”, more preferably a halogen atom and a tert-butyl group, most preferably a halogen atom It is.
- ring Z it is represented by “Formula — 0—A (where A is as defined above) and Formula—X—E (where X and E are as defined above) An arene which may have a substituent in addition to the group ”.
- heteroarenes of “heteroarenes which may further have a substituent in addition to” include, as atoms (ring atoms) constituting a ring system, heteroatones selected from an oxygen atom, a sulfur atom, a nitrogen atom, and the like.
- Monocyclic or condensed polycyclic aromatic heterocycles containing at least one of 1 to 3 atoms include, for example, a furan ring, a thiophene ring, a pyrrole ring, an oxazole ring, an isoxazole ring, a thiazole ring, and an isothiazole.
- Examples of the “aryl group” of the “aryl group optionally having substituent (s)” in the definition of ⁇ include the same groups as the “aryl group” in the definition of the above “hydrocarbon group”. There are CsCi such as phenyl group, 1-naphthyl group and 2-naphthyl group. And most preferably a phenyl group.
- the position of the substituent on the aryl group is not particularly limited. When two or more substituents are present, they may be the same or different.
- the “aryl group optionally having substituent (s)” in the definition of E is “a phenyl group optionally having substituent (s)”, it is preferably a “monosubstituted phenyl group”, And “disubstituted phenyl group”, and more preferably “disubstituted phenyl group”.
- aryl group optionally having substituent (s) in the definition of E above, “disubstituted phenyl group”, specific examples of suitable groups include the following “substituent group 5 _le”. The groups shown are listed.
- aryl group optionally having substituent (s) in the definition of E is “disubstituted phenyl group”, more preferably, “2,5-disubstituted phenyl group” and “3,5 Di-substituted phenyl group ".
- the “aryl group optionally having substituent (s)” S is preferably a “2,5-disubstituted phenyl group”, more preferably a “2,5-disubstituted phenyl group ( ⁇ And at least one of the substituents is a trifluoromethyl group) ”, more preferably a group selected from the following“ substituent group ⁇ -3e ”, and most preferably Is a 2,5_bis (trifluoromethyl) phenyl group.
- aryl group optionally having substituent (s) is “3,5-disubstituted phenyl group”
- substituent At least one is a trifluoromethyl group
- the substituent At least one is a trifluoromethyl group
- aryl group optionally having substituent (s) in the definition of E is a “monosubstituted phenyl group”, a specific example of a suitable group includes a biphenyl-4-yl group.
- heteroaryl group of the “heteroaryl group optionally having substituent (s)” in the definition of E includes the “monocyclic heteroaryl group” and the “condensed polycyclic group” in the definition of the above “heterocyclic group”.
- the same groups as in the "heteroaryl group of the formula" can be mentioned.
- it is a 5-membered heteroaryl group, most preferably a thiazolyl group.
- substitution position of the substituent on the heteroaryl group is not particularly limited. When two or more substituents are present, they may be the same or different.
- Heteroaryl group which may have a substituent in the definition of E above force S "substitution When it is a "thiazolyl group which may have a group”, it is more preferably a “thiazole-2-yl group which may have a substituent", and more preferably, a "disubstituted thialyl group”.
- Sol-2-yl group and most preferably 4 _ [(1,1-dimethyl) ethyl] 1-5-[(2,2-dimethyl) propionyl] thiazol-2-yl group.
- the compound represented by the general formula (1_1) will be specifically described.
- the same groups as the “substituents” in “may have a substituent” are exemplified.
- the position of the substituent on the acyl group is not particularly limited. When two or more substituents are present, they may be the same or different.
- a 1 which may have a substituent Ashiru group (except for unsubstituted Asechiru group and an unsubstituted Akuriroiru group)” include, preferably, below “location substituent group ⁇ ", and more preferably, a heterocyclic monocarbyl group which may have a substituent, a force phono group which may have a substituent, and It is a labamoyl group which may have a substituent.
- Substituent group Hydrocarbon optionally having substituent (s), heterocyclic optionally having substituent (s), hydrocarbon optionally having substituent (s) Oxycarbonyl group, hydrocarbon-sulfonyl group optionally having substituent (s), sulfamoyl group optionally having substituent (s), sulfo group optionally having substituent (s), having substituent (s) Force phono group, and optionally substituted rubamoyl group
- acyl group in the definition of ⁇ ⁇ 1 above
- the “heterocyclic group” includes the same groups as the “heterocyclic group” in the above definition.
- ⁇ optionally substituted acyl group '' in the definition of A 1 above is ⁇ an optionally substituted heterocyclic monovalent ruponyl group ''
- suitable groups include And the following groups represented by “substituent group ⁇ 1 —la”.
- the “optionally substituted acyl group” in the definition of A 1 above is an “optionally substituted heterocyclic monovalent sulfonyl group”, more preferably, “5 to A 6-membered non-aromatic heterocyclic monocarbonyl group containing at least one nitrogen atom as an atom (ring atom) constituting the hetero ring, and a carbonyl group bonded through a nitrogen atom And more preferably, a (pyrrolidine-11-yl) carbonyl group, a (morpholine — 41-yl) carbonyl group, a (4-methylbiperazine-11-yl) carbonyl group, (Ethoxycarbonyl) piperidine-11-yl] carbonyl group, and (4-canolepoxypiperidine-11-yl) carbonyl group, and most preferably, (monoreforin-1-yl).
- Yl) is a carbinole group.
- acyl group in the definition of A 1 above is a force S “an optionally substituted force phono group”, preferably a force phono group, and It is a dibenzylforce phono group, and more preferably a force phono group.
- acyl group and the “optionally substituted carpamoyl group” in the definition of A 1 above, more preferably “N, N-disubstitution power rubamoyl” And more preferably N, N-dimethylcarbamoyl, N, N-getylcarbamoyl, N-methyl-N-phenylcarbamoyl, N, N-bis [(ethoxycarbonyl) methyl] And N, N-bis (carboxymethinole) canolebamoinole group.
- an optionally substituted acyl group '' f If ⁇ an optionally substituted hydrocarbon mono-oxyl propyl group '' is a specific example of a suitable group Is a methoxycarbonyl group.
- ⁇ optionally substituted acyl group '' in the above definition of A 1 is ⁇ optionally substituted hydrocarbon-sulfonyl group ''
- suitable groups include: Methanesulfonyl group [mesyl group], prono. And a isopropylsulfonyl group, and a p-toluenesulfonyl group [tosyl group].
- ⁇ optionally substituted acyl group '' in the definition of A 1 above is S ⁇ an optionally substituted sulfamoyl group ''
- suitable groups include N, N — A dimethylsulfamoyl group.
- Optionally substituted acyl group” in the definition of A 1 above “S” is a 5- to 6-membered non-aromatic heterocycle-carbonyl group, and an atom (ring atom ) Is a group that contains at least one nitrogen atom and is linked via a nitrogen atom "and" N, N-disubstituted rubamoyl group " , “N, N-disubstituted rubamoyl group (two positions of the carbamoyl group)
- the substituents may together form a nitrogen-containing heterocyclic group which may have a substituent together with the nitrogen atom to which the substituent is attached) ".
- suitable groups include (pyrrolidine-11-yl) carbonyl group, (morpholine-1-yl) carbonyl group, and (4-methylbiperazine-11-yl) caprolitol.
- (Morpholine-141-yl) carbonyl group is preferably, benzyl group, (4-eth
- alkyl group of rCi Ce” of the “alkyl group of Ci Cs which may have a substituent” in the definition of A 1 include, for example, methyl, ethyl, n-propyl, isopropyl, n-butynole, isobutynole , Sec-Putinole, tert-Putinole, n-Pentyl, Isopentinole, 2-Methynolebutinole, 1-Methinolebutyl, Neopentyl, 1,2-Dimethylpropyl, 1-Ethylpropyl, n-Hexyl, 4-Methylpentyl, 3-Methylpentyl , 2-Methylpentyl, 1-Methylpentyl, 3,3-Dimethylbutyl, 2,2-Dimethylbutyl, 1,1-Dimethylbutyl, 1,2-Dimethinoleptyl,
- alkyl group optionally Ci Ce may have a substituent in the definition of the A 1 is the following "substituent group ⁇ 1 - 4 a 'include groups shown.
- the “C 1 -C 6 alkyl group optionally having substituent (s)” in the definition of A 1 above is more preferably an acyloxymethylene group optionally having substituent (s). Particularly preferred are an acetoxmethyl group, a (piparyloxy) methyl group, a 1- (ethoxycarbonyloxy) ethyl group, a [(piperidinocarbonyl) oxy] methyl group, and a [(morpholinocarbonyl) methyl group.
- Methyl group ( ⁇ [[4- (ethoxycarbonyl) piperidine-1-1yl] carbonyl] oxy) Methyl group, ⁇ [((4- ethoxycarbonyl) piperidine-1-1yl) propylonyl] oxy ⁇ Methyl group, ( ⁇ N, N-bis [(ethoxycarbonyl) methyl] potassium) methyl group, and ⁇ [N, N-bis (carboxymethyl) potassium] oxy ⁇ methyl group is there.
- a 1 may combine with one CONH— group to form a ring structure which may have a substituent.
- preferred specific examples of the compound represented by the general formula (1-1) include a compound represented by the following formula:
- ring Z 1 it is represented by “Formula I O—A 1 (where A 1 is as defined above) and Formula I CONH—E 1 (where E 1 is as defined above)
- the “arenes” of the “arenes which may further have a substituent in addition to the group to be formed” include monocyclic or condensed polycyclic aromatic hydrocarbons, for example, benzene ring, naphthalene ring , An enracene ring, a phenanthrene ring, an acenaphthylene ring and the like.
- Cs Ci such as a benzene ring and a naphthalene ring.
- a benzene ring and a naphthalene ring and most preferably a benzene ring.
- a benzene ring having two substituents and more preferably a benzene ring having the formula —O—A 1 (formula Wherein A 1 has the same meaning as defined above) and the group represented by the formula CONH-E 1 (wherein, E 1 has the same meaning as defined above), and further has one substituent "Benzene ring".
- substituent group ⁇ 1 - 1 ⁇ is a group selected either et al., Further preferably Bruno, androgenic atom ⁇ Pi ter 1 _ butyl [( 1,1-dimethyl) ethyl group], and most preferably a halogen atom.
- R zl is preferably the following “Substituent group ⁇ And more preferably a halogen atom and a tert-butyl group, most preferably a halogen atom.
- heteroarenes of the “heteroarenes which may further have substituents in addition to the groups represented” include oxygen atoms, sulfur atoms, nitrogen atoms and the like as atoms (ring atoms) constituting a ring system. And monocyclic or condensed polycyclic aromatic heterocycles containing at least one heteroatom selected from the group consisting of, for example, a furan ring, a thiophene ring, a pyrrole ring, an oxazole ring, and an isooxazole ring.
- Ariru group of the "optionally substituted Ariru group” in E 1 defined above same groups as “Ariru group” in the definition of "hydrocarbon group” and the like, preferably And a phenyl group, a 1-naphthyl group, a 2-naphthyl group and other C 6 -C 10 aryl groups, most preferably a phenyl group.
- the “substituent” of the “optionally substituted aryl group” in the definition of E 1 above is the same as the “substituent” in the definition of “optionally substituted” above. Is mentioned.
- the substitution position of the substituent on the aryl group is not particularly limited. When two or more substituents are present, they may be the same or different.
- the “optionally substituted aryl group” in the definition of E 1 above is a “optionally substituted phenyl group”, it is preferably a “monosubstituted phenyl group” And "disubstituted phenyl group”, and more preferably "disubstituted phenyl group”.
- aryl group optionally having substituent (s) in the definition of E 1 is a “disubstituted phenyl group”
- suitable groups include the following “substituent group ⁇ 1 — 1 e The group shown by "is mentioned.
- the “aryl group optionally having substituent (s)” is a “2,5-disubstituted phenyl group”, and more preferably, a “2,5-disubstituted phenyl group ( Provided that at least one of the substituents is a trifluoromethyl group), and more preferably, a group selected from the following substituent group S i -S ej, Some are 2,5-bis (trifluoromethyl) phenyl groups.
- aryl group optionally having substituent (s) is a “3,5-disubstituted phenyl group”, more preferably “3,5-disubstituted phenyl group” (provided that the substituent At least one is a trifluoromethyl group) ”, particularly preferably a group selected from the following“ substituent group ⁇ 1 — 5 e ”, and most preferably 3,5-bis (trinoleolomethinole) phenyl group.
- ⁇ aryl group optionally having substituent (s) '' in the definition of E 1 above is ⁇ monosubstituted phenyl group ''
- suitable groups include biphenyl-41-yl group.
- heteroaryl group of the “heteroaryl group optionally having substituent (s)” in the definition of E 1 includes the “monocyclic heteroaryl group” and the “condensed heterocyclic group” in the definition of the above “heterocyclic group”. And the same groups as the “polycyclic heteroaryl group”. Preferably it is a 5-membered heteroaryl group, most preferably a thiazolyl group.
- substitution position of the substituent on the heteroaryl group is not particularly limited. When two or more substituents are present, they may be the same or different.
- ⁇ heteroaryl group optionally having substituent (s) '' in the definition of the above E 1 is ⁇ thiazolyl group optionally having substituent (s) '', preferably A thiazole-2-yl group which may be optionally present, more preferably a "disubstituted thiazol-2-yl group", and particularly preferably a "disubstituted thiazol-2-yl group". Most preferably, it is a 4-[(1,1-dimethyl) ethyl] -5-[(2,2-dimethyl) propionyl] thiazole-2-izure group.
- the compound represented by the above general formula (I) is preferably a compound represented by the following general formula (X-1) And / or a compound other than the compound represented by the following compound group II ”.
- . 1 is the following general formula (X—2):
- R 1Q. 3, R 1 ( ) ° 4 and R 1 () ° 5 are each independently a hydrogen atom, an alkyl group or an alkoxy group with carbon number from 1 to 6 1 to 6 carbon atoms, R 1 °° 9 and R 1 ° 1 each independently represent a hydrogen atom, an alkyl group having 1 to 6 carbon atoms or an acyl group having 2 to 11 carbon atoms);
- G 2 is a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms which may be substituted, an aryl group having 6 to 12 carbon atoms which may be substituted, 4 to 11 carbon atoms which may be substituted A heteroaryl group, an optionally substituted aralkyl group having 7 to 14 carbon atoms, an optionally substituted heteroaryl alkyl group having 5 to 13 carbon atoms, or an acyl group having 2 to 11 carbon atoms A group;
- X 1QD1 represents a carboxyl group which may be esterified / esterified or amidated.
- the compound defined by the above general formula (I-1) or a pharmacologically acceptable salt thereof, or a hydrate or solvate thereof is a novel compound, and is a compound based on the present invention.
- the use of is not particularly limited.
- the compounds represented by the general formulas (I) and (I-11) can form salts.
- a metal salt such as a lithium salt, a sodium salt, a potassium salt, a magnesium salt, or a calcium salt, or an ammonium salt or a methyl ammonium salt
- Ammonium salts such as salt, dimethylammonium salt, trimethylammonium salt, and dihexylhexylammonium salt.
- a basic group for example, hydrochloride
- Mineral salts such as bromates, sulfates, nitrates, and phosphates, or methanesulfonate, benzenesulfonate, paratoluenesulfonate, acetate, propionate, tartrate, and fumaric acid Organic salts, maleates, malates, oxalates, succinates, citrates, benzoates, mandelates, caycinates,
- the compounds represented by the above general formulas (I) and (I-11) or salts thereof may exist as hydrates or solvates in some cases. Any of the above substances may be used as an active ingredient of the medicament of the present invention. Further, the compounds represented by the general formulas (I) and (1-1) may have one or more asymmetric carbon atoms, and may exist as stereoisomers such as optically active diastereomers.
- the active ingredient of the medicament of the present invention a pure form of a stereoisomer, an arbitrary mixture of an optical enantiomer or a diastereomer, a racemic body and the like may be used.
- the compounds represented by the general formulas (I) and (1-1) have, for example, a 2-hydroxypyridine structure, they exist as a 2-pyridone structure which is a tautomer thereof. There are cases.
- a tautomer in a pure form or a mixture thereof may be used.
- the configuration may be either Z 1 configuration or E configuration.
- geometric isomers in any arrangement or a mixture thereof may be used.
- M e methinole group
- E t ethynole group
- Protecting group for a hydrogen atom or a hydroxy group preferably, an alkyl group such as a methyl group; an aralkyl group such as a benzyl group; an acetyl group; an alkoxyalkyl group such as a methoxymethyl group
- an alkyl group such as a methyl group
- an aralkyl group such as a benzyl group
- an acetyl group an alkoxyalkyl group such as a methoxymethyl group
- This reaction is carried out in the presence of an acid halogenating agent or a dehydrating condensing agent, in the presence or absence of a base, in a solvent-free or aprotic solvent at a reaction temperature of 0 ° C to 180 ° C.
- This reaction is carried out in the presence of an acid halogenating agent or a dehydrating condensing agent, in the presence or absence of a base, in a solvent-free or aprotic solvent at a reaction temperature of 0 ° (° 180 ° C.).
- Examples of the acid halogenating agent include, for example, chloridion thionyl, thionyl bromide, sulfuryl chloride, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride, and the like when A 1 Q1 is a hydrogen atom.
- phosphorus trichloride is A 1 Q1 is an acetyl group or the like, oxychloride phosphorus is preferred.
- Examples of the dehydrating condensing agent include N, N, dicyclohexyl carbodiimide, 1-ethyl-13- (3-dimethylaminopropyl) carbodiimide hydrochloride, diphenylforceforyl azide and the like. .
- Examples of the base include inorganic bases such as sodium carbonate, carbonated carbonate, sodium hydrogencarbonate, and the like, and organic bases such as pyridine, triethylamine, and N, N-ethylethylaniline.
- Examples of aprotic solvents include dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 1,4-dioxane, benzene, tolene, monochrome benzene, o-dichloromouth benzene, N, N-dimethinophorenolemamide, N-methylpyrrolidone and the like can be mentioned.
- an acid halogenating agent toluene, monochlorobenzene, and o-dichlorobenzene are particularly preferred.
- the target amide can also be produced by previously producing and isolating an acid chloride from a carboxylic acid by a method according to the above, followed by reacting with an amine having E1Q1.
- Suitable reaction conditions when G is a hydroxy group include, for example, "Archiv der Pharmazie", (Germany), 1998, Vol. 331, No. 1, p.
- the reaction conditions described in can be used.
- the types of the carboxylic acid derivative (1) and the amine (2) are not particularly limited, and may be newly synthesized with appropriate reference to a known production method in the literature, or a commercially available reagent may be obtained and used in the above reaction. Can be.
- the amide (3) has a protecting group and / or a substituent which is advantageous for functional group modification (for example, an amino group and its protected or precursor; a carboxy group and its protected or precursor; a hydroxy group Amide (4) can be produced by carrying out a deprotection reaction and a functional or functional group modification reaction in this step.
- a deprotection reaction and a functional group modification reaction include, for example, Theodora W. Green and Peter 'G. M. M. Buch. GM Wuts) Ed.
- X represents another linking group (eg, one S ⁇ 2 NH—, one NHCO—, -NH S ⁇ 2 —, one CONHCH 2 —, one CONHCH 2 CH 2 —, -CONHCH 2 CO NH—, one CONHNHCO—, one CONHNHCH 2 —, one COO—, one CO NHNH—; the hydrogen atom on the linking group may be substituted). Therefore, it is applicable.
- the compound in which A is a hydrogen atom and X is _CH 2 NH— can be produced, for example, by the method shown in Reaction Scheme 2.
- rings Z and E have the same meanings as defined in formula (I), and
- a 2Q1 is a hydrogen atom or a protecting group for a hydroxy group (preferably an alkyl group such as a methyl group; a benzyl group) Aralkyl group; acetyl group; alkoxyalkyl group such as methoxymethyl group; substituted silyl group such as trimethylsilyl group)
- an imine derivative of the formula (7) can be produced by dehydrating and condensing an aldehyde (5) and an amine (6). This reaction is carried out in a solvent at a reaction temperature of 0 ° C to 100 ° C in the presence or absence of a dehydrating agent.
- the dehydrating agent include anhydrous magnesium sulfate and molecular sieve.
- the solvent include non-reactive solvents. Tetrahydrofuran, 1,4-dioxane, methanol, ethanol and the like are preferable.
- X is another linking group (eg, one CONHN-CH—, —CH-NNH CO—, —CHNNH—; a hydrogen atom on the linking group may be substituted).
- a 2D1 of Imin derivative (7) is a protecting group for a hydroxy group, by deprotection reaction, it is possible to produce the compound A 2Q1 is a hydrogen atom.
- the anti Various known methods can be used, for example, "Protective" Gnorapes Inn, edited by Theodora W. Green (Theodora W. Green), Peter G. ⁇ ⁇ , Peter GM Wuts.
- the target compound (8) can be produced by reducing the imine derivative (7).
- This reaction is carried out in a solvent at a reaction temperature of 0 ° C to 100 ° C in the presence of a reducing agent.
- the reducing agent include sodium hydrogen fluoride and lithium hydrogen hydride.
- the solvent include non-reactive solvents, and preferred are tetrahydrofuran, 1,4-dioxane, methanol, ethanol and the like.
- This reaction is also performed by a catalytic hydrogenation method.
- the catalyst include palladium carbon, platinum carbon, palladium hydroxide, and palladium black.
- the solvent examples include non-reactive solvents, and preferred are tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water and the like.
- the reaction is carried out at a reaction temperature of 0 ° C to 20 ° C, and the hydrogen pressure is normal pressure or under pressure.
- the compound in which X is represented by —CH—CH— (the hydrogen atom on the linking group may be substituted) is, for example, a compound represented by reaction scheme 3-1 or reaction scheme It can be manufactured by the method shown in 3-2.
- W 301 represents o, o, di-hydrocarbon-force phono group or triarylforce fonn group. Represents a group
- the target compound (11) By subjecting the aldehyde (9-11) and the phosphorus compound (10-1) to dehydration condensation, the target compound (11) can be produced.
- This reaction is carried out in a solvent at a reaction temperature of 0 ° C to the boiling point of the solvent in the presence of a base.
- the base include inorganic bases such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate, and organic bases such as pyridine, triethylamine, N, N-getylaniline and the like.
- the solvent include non-reactive solvents, and preferred are tetrahydrofuran, 14-dioxane, methanol, ethanol, water and the like.
- W 302 represents a halogen atom (preferably iodine atom or bromine atom), (trifluoromethanesulfoell) oxy group, etc.)
- the target compound (11) By subjecting the halide (9-1-2) and the styrene derivative (10-2) to a coupling reaction in the presence of a transition metal complex catalyst, the target compound (11) can be produced.
- This reaction is performed in a solvent at a reaction temperature of 0 ° C to the boiling point of the solvent in the presence of a transition metal complex catalyst, in the presence or absence of a ligand and a base or a base.
- the transition metal complex catalyst include palladium acetate, dichlorobis (triphenyl) Force fin) Palladium-based catalysts such as palladium.
- the ligand include force fin-based ligands such as triphenylphenyl fin.
- Examples of the base include inorganic bases such as sodium carbonate, potassium carbonate, and sodium hydrogencarbonate, and organic bases such as pyridine, triethylamine, and N, N-ethylethylaniline.
- Examples of the solvent include non-reactive solvents, and N, N-dimethylformamide, tetrahydrofuran, 1,4-dioxane and the like are preferable.
- the desired compound enone (14) can be produced by dehydrating and condensing a ketone (12) and an aldehyde (13). This reaction is carried out in a solvent at a reaction temperature of 0 ° C. to the boiling point of the solvent in the presence of a base.
- the base include inorganic bases such as sodium hydroxide, hydroxide hydroxide, sodium carbonate, potassium carbonate, sodium hydrogencarbonate, and the like, and organic bases such as pyridine, triethylamine, N, N-getylaniline and the like.
- Non-reactive solvents are exemplified, but tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water and the like are preferred.
- the target compound (15) can be produced by reducing enone (14).
- This reaction is carried out in a solvent in the presence of a reducing agent at a reaction temperature of 0 ° C to 100 ° C.
- a reducing agent Phosphorous sodium hydride, hydrogenation phos Lithium and the like can be mentioned.
- the solvent include non-reactive solvents, and preferred are tetrahydrofuran, 1,4-dioxane, methanol, ethanol, and the like.
- This reaction is also performed by a catalytic hydrogenation method.
- the catalyst include palladium carbon, platinum carbon, palladium hydroxide, and palladium black.
- the solvent include non-reactive solvents.
- the reaction is carried out at a reaction temperature of 0 ° C to 20 ° C, and the hydrogen pressure is normal pressure or under pressure.
- the compound in which X is -NHCONH- (the hydrogen atom on the linking group may be substituted) can be produced, for example, by the method shown in Reaction Scheme 5. can do.
- the target compound, urea (18) can be produced.
- This reaction is carried out in a solvent at a reaction temperature of 0 ° C to the boiling point of the solvent in the presence or absence of a base.
- the base include inorganic bases such as sodium hydroxide, hydroxylated sodium hydroxide, sodium carbonate, carbonated sodium carbonate, sodium hydrogencarbonate, and the like, and organic bases such as pyridine, triethylamine, N, N-ethylalanine and the like.
- examples include non-reactive solvents, but preferred are tetrahydrofuran, 1,4-dioxane, methanol, ethanol, water and the like.
- A is an optionally substituted acyl group (excluding an unsubstituted acetyl group and an unsubstituted acryloyl group), or A compound which represents a C i C e alkyl group which may be substituted or which is bonded to a linking group X to form a ring structure which may have a substituent (reaction scheme) 6).
- Examples of the acylation reaction include a dehydration condensation reaction with a carboxylic acid, an acid halide of a carboxylic acid, a carboxylic anhydride, an acid halide of a sulfonate, an anhydride of a sulfonate, an acid halide of a phosphoric acid, or Examples of the substitution reaction include phosphoric anhydride and the like, addition reactions with isocyanate, isothiothionate, sulfur trioxide and the like.
- Examples of the alkylation reaction include substitution reaction with an alkyl halide and the like. .
- the dehydration condensation reaction between the hydroxyaryl derivative (19) and the carboxylic acid is carried out in the presence of an acid halide agent or a dehydration condensing agent, in the presence or absence of a base, in a solvent-free or nonprotonic solvent.
- the reaction is performed at a reaction temperature of 0 ° C to 180 ° C.
- the acid halogenating agent include thionyl chloride, thionyl bromide, sulfuryl chloride, phosphorus oxychloride, phosphorus trichloride, phosphorus pentachloride and the like.
- Examples of the dehydration condensing agent include N, N, 1-dicyclohexylcarpoimide, 1-ethyl-3- (3-dimethylaminopropyl) carbopimid hydrochloride, diphenylfosforylazide and the like.
- Examples of the base include inorganic bases such as sodium carbonate, potassium carbonate and sodium hydrogen carbonate, and organic bases such as pyridine, triethylamine, N, N-diethylaniline and the like.
- Dichroic mouth as a non-protonic solvent
- examples include methane, dichloroethane, chlorofornolem, tetrahydrofuran, 1,4-dioxane, benzene, tonolen, monochrome benzene, o-dichlorobenzene, N, N-dimethylformamide, and N-methylpyrrolidone.
- an acid halogenating agent in particular, toluene, monochlorobenzene, and o-dichlorobenzene are preferred.
- Substitution reaction of hydroxyaryl derivative (19) with carboxylic acid halide, carboxylic anhydride, sulfonic acid acid halide, sulfonic acid anhydride, phosphoric acid acid halide or phosphoric anhydride Is carried out in the presence or absence of a base in a solvent-free or aprotic solvent at a reaction temperature of ⁇ 50 ° C. to 180 ° C.
- the base include inorganic bases such as sodium carbonate, lium carbonate, sodium hydrogen carbonate, and the like, or organic bases such as pyridine, triethylamine, N, N-getylaniline.
- Examples of aprotic solvents include dichloromethane, dichloroethane, chloroforenolem, tetrahydrofuran, 1,4-dioxane, benzene, tonolene, monochrome benzene, o-dichloro mouth benzene, N, N-dimethinolefor / rem amide, N —Methylpyrrolidone and the like.
- the compound in which A is (morpholine-14-yl) carboxyl group is a compound represented by the following formulas: hydroxyaryl derivative (19) and (monoreforin-141) carbonyl carbonyl Can be produced by reacting the compound in tetrahydrofuran in the presence of triethylamine and 4-dimethylaminopyridine.
- the compound in which A is a dibenzylforcephono group can be prepared by reacting a hydroxyaryl derivative (19) with dibenzyl phosphite in the presence of diisopropylethylamine and 4-dimethylaminopyridine. It can be produced by reacting in Shiridani carbon.
- the compound wherein A is a sulfo group can be produced by reacting the hydroxyaryl derivative (19) with a complex of thiopyridine and pyridine in pyridine.
- a hydroxyaryl derivative (19) in which X is a —CO NH— group and ethyl chloroformate were heated to reflux in pyridine, the hydroxy group on the ring Z and one CONH— were bonded via a Carboel group.
- a compound can be obtained.
- the addition reaction of the hydroxyaryl derivative (19) with isocyanate, isothiocyanate, sulfur trioxide and the like is carried out in the presence or absence of a base in a solvent-free or aprotic solvent at 50 ° C to 18 ° C.
- the reaction is performed at a reaction temperature of 0 ° C.
- the base include inorganic bases such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate, and organic bases such as pyridine, triethylamine, N, N-getylaniline and the like.
- Non-protonic solvents include dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 1,4-dioxane, benzene, tonolen, monochrome benzene, o-dichlorobenzene, N, N-dimethylformamide, N-methyl vilolidone and the like can be mentioned.
- the substitution reaction between the hydroxyarinole derivative (19) and the alkyl halide is carried out in a solvent-free or aprotic solvent in the presence or absence of a base at a reaction temperature of 50 ° C to 180 ° C. Done.
- a base include inorganic bases such as sodium carbonate, potassium carbonate, and sodium hydrogen carbonate, and organic bases such as pyridine, triethylamine, and N, N-ethylethylphosphine.
- aprotic solvents examples include dichloromethane, dichloroethane, chloroform, tetrahydrofuran, 1,4-dioxane, benzene, tonolene, monochlorobenzene, o-dichlorobenzene, N, N-dimethylformamide, N-methylpyrrolidone, etc. Can be mentioned.
- each reaction using the above hydroxyaryl derivative (19) each reaction can be carried out after converting (19) into a metal salt such as a sodium salt or a potassium salt.
- a deprotection reaction and / or a functional group modification reaction are performed.
- I can.
- Various known methods can be used for the reaction. Examples of the deprotection reaction and the functional group modification reaction include, for example, Theodora W. Green, Peter G. (Peter GM Wuts), Protective Groups in Organic Syntheses J, (USA), 3rd edition, John Wiley & Sons, Inc.
- the compounds represented by the general formulas (I) and (I-11) produced by the above methods can be prepared by methods known to those skilled in the art, for example, extraction, precipitation, fractional chromatography, fractional crystallization, It can be isolated and purified by turbid washing, recrystallization, etc. Also, pharmacologically acceptable salts of the compounds of the present invention, and hydrates and solvates thereof, can be produced by methods well known to those skilled in the art.
- the compounds of the present invention represented by the general formulas (I) and (1-1) have an inhibitory action on NF- ⁇ ⁇ ⁇ activation and an inhibitory action on inflammatory cytokine production release, and inhibit NF- ⁇ activation. It is useful as an active ingredient of a medicament such as a drug or an inflammatory cytokine production release inhibitor.
- a medicament such as a drug or an inflammatory cytokine production release inhibitor.
- the above medicines include tumor necrosis factor (TNF), interleukin-1, interleukin-1, interleukin-16, interleukin-18, granulocyte colony stimulating factor, interferon, and ICAM, a cell adhesion factor.
- the above-mentioned medicament is useful as a medicament for preventing and / or treating diseases caused by NF- ⁇ B activation and diseases caused by excessive inflammatory cytokine production.
- the compounds of the present invention represented by the general formulas (I) and (1-1) can be used to produce the desired inflammatory cytokine without affecting other signal transduction pathways, that is, without showing any serious side effects. It shows an inhibitory effect on the production release of liposomes and the production of inflammatory cell adhesion molecules. NF- ⁇ activation is induced by external stimuli, and proteins such as inflammatory cytokines are expressed.
- TNF- ⁇ and interleukin (IL) -1 are among the inflammatory cytokines, and their gene expression itself is NF — Positively controlled by ⁇ ⁇ to form a positive feedback 'loop [TNF- ⁇ ; ⁇ NF—KB ⁇ TNF- ⁇ ], which is thought to play a role in the chronic inflammation (No. 18th Annual Meeting of Japanese Society of Inflammation, Shin Theme “The mechanism of action and new developments of antirheumatic drugs", Tokyo, 2000). Therefore, the compound of the present invention can be used as a highly effective medicament against chronic inflammatory diseases and diseases caused by TNF-a and IL-11. More specifically, the medicament of the present invention, the disease is an NF-?
- K activation ⁇ Pi ⁇ or of B as follows believed inflammatory 14 cytokines are involved, such as rheumatoid rheumatism, degenerative Arthropathy, systemic lupus erythematosus, systemic scleroderma, polymyositis, Sheddalen syndrome, vasculitis syndrome, antiphospholipid antibody syndrome, Still's disease, Behcet's disease, periarteritis nodosa, ulcerative colitis , Crohn's disease, active chronic hepatitis, autoimmune diseases such as glomerulonephritis, chronic nephritis, chronic prostatitis, gout, atherosclerosis, multiple sclerosis, arteriosclerosis, intimal thickening, psoriasis, psoriasis Allergic diseases such as arthritis, contact dermatitis, arterial dermatitis, hay fever, asthma, bronchitis, interstitial pneumonia, lung disease with granulomas, chronic
- the medicament of the present invention include osteoporosis, such as metabolic bone diseases such as bone cancer pain It is also useful for prevention and treatment of Z. It can also be used to prevent organ deterioration during pre-transplant organ storage.
- the active ingredient of the medicament of the present invention compounds represented by the general formulas (I) and (I-11), and pharmacologically acceptable salts thereof, and hydrates thereof and their solutions
- One or more kinds of substances selected from the group consisting of solvates can be used.
- the above-mentioned substance itself may be used as the medicament of the present invention.
- the medicament of the present invention is used as an active ingredient and one or more pharmaceutically acceptable additives for pharmaceutical preparations.
- a pharmaceutical composition comprising: In the above pharmaceutical composition, the ratio of the active ingredient to the pharmaceutical additive is about 1% to 90% by weight.
- Some of the compounds represented by the general formulas (I) and (1 -1) translocate into the blood by oral administration, and then undergo chemical modification such as hydrolysis by the action of esterase in the blood. receiving, NF-? kappa changed to another compound having a B activation inhibitory action.
- Compounds having such properties can be used as so-called “prodrugs”, but it goes without saying that the above-mentioned usage forms are included in the scope of the present invention.
- the medicament of the present invention can be administered, for example, as a pharmaceutical composition for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, or liquids.
- a pharmaceutical composition for oral administration such as granules, fine granules, powders, hard capsules, soft capsules, syrups, emulsions, suspensions, or liquids.
- It can also be administered as a pharmaceutical composition for parenteral administration.
- a preparation prepared as a pharmaceutical composition in powder form may be dissolved at the time of use and used as an injection or infusion.
- solid or liquid pharmaceutical additives can be used for the production of pharmaceutical compositions.
- Pharmaceutical additives may be either organic or inorganic. That is, when an oral solid preparation is manufactured, the active ingredient is used as an excipient and, if necessary, a binder, a disintegrant, and a lubricant. After the addition of an agent, a coloring agent, a flavoring agent, and the like, a tablet, a coated tablet, a granule, a powder, a capsule and the like can be prepared by a conventional method.
- the excipient used include lactose, sucrose, sucrose, glucose, corn starch, starch, talc, sorbite, crystalline cellulose, dextrin, kaolin, calcium carbonate, silicon dioxide, and the like.
- binder examples include polyvinylinoleanol, polyvinylinoleatenole, ethylsenorelose, methinoresenorelose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylcellulose, hydroxypropyl methinole cellulose, Canolecum citrate, dextrin, pectin and the like can be mentioned.
- lubricant examples include magnesium stearate, tanolek, polyethylene glycol, silica, and hardened spot oil. Any coloring agent that is normally permitted to be added to pharmaceuticals can be used.
- cocoa powder As a flavoring agent, cocoa powder, heart-shaped brain, aromatic acid, heart-shaped oil, dragon brain, cinnamon powder and the like can be used. These tablets and granules can be sugar-coated, gelatin-coated and optionally coated as required. Further, a preservative, an antioxidant, and the like can be added as needed.
- liquid preparations for oral administration such as emulsions, syrups, suspensions and solutions
- inert diluents such as water or vegetable oils
- the preparation can contain adjuvants such as wetting agents, suspending aids, sweetening agents, fragrances, coloring agents or preservatives.
- the liquid preparation may be filled into capsules of an absorbable substance such as gelatin.
- Preparations for parenteral administration include, for example, water, propylene glycol, polyethylene glycol, benzyl alcohol, ethyl oleate, and lecithin Can be.
- As the base used in the production of suppositories for example, cocoa butter, emulsified cocoa butter, lauric fat, and willitebtusol can be mentioned.
- the method for preparing the preparation is not particularly limited, and any method commonly used in the art can be used.
- diluents such as water, ethyl alcohol, macrogol, propylene glycol, citric acid, acetic acid, phosphoric acid, lactic acid, sodium lactate, sulfuric acid and sodium hydroxide PH adjusters and buffers, such as sodium taenoate, sodium acetate and sodium phosphate; and stabilizers, such as sodium pyrosulfite, ethylenediaminetetraacetic acid, tiodicholic acid and thiolactic acid.
- a sufficient amount of salt, bud sugar, mannitol, or glycerin to prepare an isotonic solution may be incorporated into the preparation. Agents and the like can also be used.
- ointments for example, pastes, creams and gels, commonly used bases, stabilizers, wetting agents, preservatives, etc. can be added as necessary, and The ingredients can be mixed and formulated.
- the base for example, white cellulose, polyethylene, paraffin, glycerin, cellulose derivative, polyethylene glycol, silicon, bentonite and the like can be used.
- a preservative methyl paraoxybenzoate, ethyl ethyl paraoxybenzoate, propyl paraoxybenzoate and the like can be used.
- the preparation When the preparation is in the form of a patch, the above-mentioned ointment, cream, gel, paste or the like can be applied to a usual support in a conventional manner.
- a usual support woven or non-woven fabrics made of cotton, swoof and chemical fibers; films or foam sheets of soft vinyl chloride, polyethylene and polyurethane can be suitably used.
- the dose of the medicament of the present invention is not particularly limited.
- the weight of the substance, which is an active ingredient is usually 0.01 to 50,000 mg per day for an adult. It is preferable to increase or decrease the dose according to the age, disease state and symptoms of the patient.
- the above-mentioned daily dose may be administered once a day, or divided into two or three times a day at appropriate intervals, or may be administered intermittently every few days.
- the weight of the above substance, which is an active ingredient is about 0.001 to 100 mg per adult per day.
- the present invention will be described more specifically with reference to Examples, but the scope of the present invention is not limited to the following Examples.
- the compound numbers correspond to the compound numbers shown in the above table.
- a compound which was purchased from a commercially available reagent and subjected to the test as it is was included.
- the reagent vendor and the code number given in the catalog are given.
- This compound could also be obtained by using monochloro-mouth benzene instead of toluene as the reaction solvent (yield: 85.5%).
- Example 1 (1) when the method of Example 1 (1) was cited, phosphorus trichloride was used as the acid halogenating agent.
- a reaction solvent a solvent such as benzene or tolene having a monochrome mouth was used.
- the reaction mixture was diluted with ethyl acetate, washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- Example 1 5-hydroxy-1-N- [3,5_bis (trifluoromethyl) phenyl] benzamide (Example 1 (1) compound; 100 mg, 0.261 mmo1), triethylamine (50 ⁇ L, 0.359 mmo 1) in N, N-dimethylformamide (1.5 mL) solution under argon atmosphere and decanoyl chloride (7.
- Example 1 (1) 5-hydroxy-1-N- [3,5-bis (trifluoromethyl) phenyl] benzamide (Example 1 (1): 0.20 g, 0.5 2 mm o 1) was dissolved in tetrahydrofuran (5 mL), and cesyl salicyloyl chloride (0.124 g, 0.62 mmol) and triethylamine (0.2 mL, 1.43 mm o 1) were dissolved. ) was added and the mixture was stirred at room temperature for 3 hours. The reaction mixture was poured into dilute hydrochloric acid and extracted with ethyl acetate.
- Example 3 The same as in Example 3 using 5-chloro-2-hydroxy-N- [3,5-bis (trifluoromethyl) phenyl] benzamide (compound of Example 1 (1)) and phenylacetyl chloride as raw materials The operation was performed to obtain the title compound.
- Example 1 (1) 5-hydroxy-1-N- [3,5-bis (trifluoromethyl) phenyl] benzamide (Example 1 (1): 0.20 g, 0.52 mmo 1) 3,4-Methylenedioxyphenylacetic acid (103. lmg, 0.57 mmo 1), WS C ⁇ HC 1 (0.13 g, 0.68 mm o) in tetrahydrofuran (5 mL) solution of 1), 4-Dimethylaminopyridine (10 mg) was added, and the mixture was stirred for 5 hours. The reaction mixture was poured into dilute hydrochloric acid and extracted with ethyl acetate.
- Example 11 Preparation of compound No. 11 Examples of starting materials using 5-chloro-1-N-hydroxy-N- [3,5-bis (trifluoromethyl) phenyl] benzamide (compound of Example 1 (1)) and acetyloxycetyl chloride The same operation as in 3 was performed to obtain the title compound.
- Example 2 using 5-chloro-2-hydroxy-N- [3,5-bis (trifluoromethyl) phenyl] benzamide (compound of Example 1 (1)) and mono-tert-butyl malonic acid as raw materials The title compound was obtained in the same manner as in. Yield: 29.2%
- Example 2 The same as in Example 2 using 5-chloro-2-hydroxy-1-N- [3,5-bis (trifluoromethyl) phenyl] benzamide (compound of Example 1 (1)) and monopiperidinamide succinate as raw materials The operation was performed to obtain the title compound.
- Example 31 Preparation of compound No. 31
- the starting materials are 5-chloro-1-hydroxy-N- [3,5-bis (methyl triphenyleno) phenyl / le] benzamide (compound of Example 1 (1)), and N- (tert-).
- the same operation as in Example 24 was carried out using butoxycarbinone) 1L-glutamic acid ⁇ - (tert-butyl) ester to obtain the title compound.
- Example 42 Preparation of compound No. 42 (1) 2- ⁇ N- [N- (tert-butoxycarbonyl) -i j3— O— (tert-butyl) — ⁇ -L-aspartyl] 1 L-phenylalaryl ⁇ oxy-5-chloro-N— [3,5_Bis (trinoleromethyl) phenyl] benzamide As a raw material, 5-chloro-1-N-hydroxy-N- [3,5-bis (tripnoreomethyl) phenylinole] benzamide (Example 1 ( 1)) and N_ [N- (tert-butoxycanoleponinole) - ⁇ - ⁇ - (tert-butynole) -1- ⁇ -L-aspartyl] _L Same as Example 24 using L-phenylalanine The title compound was obtained.
- Example 1 5-Hydroxy-2-N-hydroxy-N- [3,5_bis (trifluoromethylinole) phenyl] benzamide (Example 1 (1) compound; 0.20 g, 0.52 mmol 1) in tetrahydrofuran (4 mL) To the solution were added triethylamine (0.15 mL, 1.07 mmol) and methanesulfoyl chloride (45 ⁇ L, 0.58 mmol), and the mixture was stirred at room temperature for 10 minutes. The reaction mixture was poured into water and extracted with ethyl acetate.
- Example 46 Preparation of compound No. 46 Using raw materials such as 5-chloro-2-hydroxy N- [3,5_bis (trifluoromethyl) phenylinole] benzamide (compound of Example 1 (1)) and 2-propanesulfuryl chloride, Example 44 The title compound was obtained in the same manner as in. Yield: 59.7%
- Example 53 Compound No. 53 This compound is a commercially available compound.
- the starting materials used are 5-methyl-1-hydroxy-N- [3,5-bis (trifluoromethyl) phenyl] benzamide (compound of Example 1 (1)) and 2-ethylisocyanatoethyl acetate as raw materials.
- the title compound was obtained in the same manner as in.
- the starting materials are 5-chloro-1-hydroxy-N- [3,5-bis (trifluoromethylinole) phenyl] benzamide (Example 1 (1) compound), and (S)-(_)-2
- Example 54 The same operation as in Example 54 was carried out using methyl isocyanato-3-phenylpropionate to obtain the title compound.
- Example 1 5-chloro-1-N-hydroxy-1-N- [3,5-bis (trifluoromethylinole) phen-nore] benzamide (Example 1 (1) compound), and (S) — (1)
- Example 54 The same operation as in Example 54 was carried out using methyl 2--2-isocyanato-3- (tert-butoxy) propionate to obtain the title compound.
- Example 66 Compound No. 66
- This compound is a commercial compound.
- the ethyl acetate layer was washed successively with water and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was washed with isopropyl ether / n-hexane, and washed. A white powder of the compound (239.3 mg, 89.0%) was obtained.
- Example 73 Preparation of compound No. 73 To a solution of triforsogen (549 mg, 1.85 mmo 1) in dichloroethane (10 mL) was added ice-cooled ethyl isodipecotate (786 mg, 5.00 mmol) and triethynoleamine (506 mg, 5. A solution of 0 Ommo 1) in dichloroethane (5 mL) was added, and the mixture was stirred at room temperature for 1 hour.
- Example 1 The same operation as in Example 1 (1) was performed using 5-bromosalicylic acid and 3,5-bis (trifluoromethyl) aniline as starting materials to obtain the title compound.
- Example 71 As in Example 71 using 2-hydroxy-5-trifluoromethyl-N- [3,5-bis (trinoleolomethinole) pheninole] benzamide and morpholine-14-canolepoyurchloride as raw materials The title compound was obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2488363A CA2488363C (en) | 2002-06-06 | 2003-06-05 | O-substituted hydroxyaryl derivatives |
KR1020047019766A KR101118807B1 (ko) | 2002-06-06 | 2003-06-05 | O-치환 히드록시아릴 유도체 |
EP03730837.6A EP1512397B1 (en) | 2002-06-06 | 2003-06-05 | O-substituted hydroxyaryl derivatives |
JP2004510775A JP4743382B2 (ja) | 2002-06-06 | 2003-06-05 | O−置換ヒドロキシアリール誘導体 |
EA200401614A EA009051B1 (ru) | 2002-06-06 | 2003-06-05 | О-замещенные гидроксиарильные производные |
US10/515,622 US7626042B2 (en) | 2002-06-06 | 2003-06-05 | O-substituted hydroxyaryl derivatives |
CN038129442A CN1658855B (zh) | 2002-06-06 | 2003-06-05 | O-取代羟基芳基衍生物 |
AU2003242118A AU2003242118B2 (en) | 2002-06-06 | 2003-06-05 | O-substituted hydroxyaryl derivatives |
US12/579,168 US20100113770A1 (en) | 2002-06-06 | 2009-10-14 | O-substituted hydroxyaryl derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-165482 | 2002-06-06 | ||
JP2002165482 | 2002-06-06 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/579,168 Continuation US20100113770A1 (en) | 2002-06-06 | 2009-10-14 | O-substituted hydroxyaryl derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003103656A1 true WO2003103656A1 (ja) | 2003-12-18 |
Family
ID=29727599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/007127 WO2003103656A1 (ja) | 2002-06-06 | 2003-06-05 | O−置換ヒドロキシアリール誘導体 |
Country Status (10)
Country | Link |
---|---|
US (2) | US7626042B2 (ja) |
EP (1) | EP1512397B1 (ja) |
JP (1) | JP4743382B2 (ja) |
KR (2) | KR101118807B1 (ja) |
CN (1) | CN1658855B (ja) |
AU (1) | AU2003242118B2 (ja) |
CA (1) | CA2488363C (ja) |
EA (1) | EA009051B1 (ja) |
TW (1) | TW200406198A (ja) |
WO (1) | WO2003103656A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006065479A2 (en) * | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting vegf production |
US7601840B2 (en) | 2004-03-15 | 2009-10-13 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
JP2015520151A (ja) * | 2012-05-08 | 2015-07-16 | エアロミクス・リミテッド・ライアビリティ・カンパニーAeromics,LLC | 新規方法 |
JP2016535787A (ja) * | 2013-11-06 | 2016-11-17 | エアロミクス・インコーポレイテッドAeromics,Inc. | 新規方法 |
JP2019521086A (ja) * | 2016-05-13 | 2019-07-25 | エアロミクス・インコーポレイテッドAeromics,Inc. | 結晶 |
WO2021114313A1 (en) * | 2019-12-14 | 2021-06-17 | Shanghai East Hospital | Ion channel antagonists/blockers and uses thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA82827C2 (en) * | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
US20060089395A1 (en) * | 2002-06-10 | 2006-04-27 | Susumu Muto | Nf-kb activation inhibitors |
EP1645288A1 (en) * | 2004-10-07 | 2006-04-12 | CTG Pharma S.r.l. | New nuclear transcription factors regulators |
US8211882B2 (en) * | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
EP2760844B1 (fr) | 2011-09-29 | 2018-11-21 | Ecole Normale Superieure De Lyon | Substrat de peptidase fluorogene |
EP2767832A1 (en) * | 2013-02-18 | 2014-08-20 | Imabiotech | Photo or chemolabile conjugates for molecules detection |
WO2015037659A1 (ja) | 2013-09-13 | 2015-03-19 | 株式会社医薬分子設計研究所 | 水溶液製剤及びその製造方法 |
US20180042873A1 (en) * | 2014-11-13 | 2018-02-15 | Aeromics, Inc. | Novel methods |
JP2018500388A (ja) * | 2014-11-18 | 2018-01-11 | ラットガーズ、ザ ステート ユニバーシティ オブ ニュージャージー | 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー |
CZ305738B6 (cs) * | 2014-12-16 | 2016-02-24 | Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové | Substituovaný derivát kyslíkatých kyselin fosforu, jeho použití a farmaceutický přípravek ho obsahující |
CN105777808B (zh) | 2014-12-23 | 2018-11-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 替唑尼特磷酸酯和烷基磺酸酯及其在药学中的应用 |
WO2017123809A1 (en) * | 2016-01-12 | 2017-07-20 | Taipei Medical University | Compounds for inhibiting cancer and virus |
WO2017201313A1 (en) | 2016-05-18 | 2017-11-23 | Shengkan Jin | Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer |
CN106588716B (zh) * | 2016-11-18 | 2019-04-09 | 浙江工业大学 | O-苯磺酰-4-三氟甲基水杨酰胺类化合物及其在制备抗肺癌药物中的应用 |
CN106748914B (zh) * | 2016-11-18 | 2019-04-09 | 浙江工业大学 | O-苯磺酰-4-三氟甲基水杨酰胺类化合物及其在制备抗胃癌药物中的应用 |
CN113382736A (zh) * | 2018-11-01 | 2021-09-10 | 加利福尼亚大学董事会 | 用于治疗雄激素介导的疾病的化合物、组合物和方法 |
CN117337182A (zh) * | 2020-08-05 | 2024-01-02 | 江苏先声药业有限公司 | 一种水通道蛋白抑制剂的药物组合物及其制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1481713A (fr) * | 1965-10-11 | 1967-05-19 | Stecker Internat S P A | Benzoazinediones et compositions germicides qui les contiennent |
US3906023A (en) * | 1971-04-28 | 1975-09-16 | Bayer Ag | Substituted-2-alkoxycarbonyloxy benzoic acid anilides |
JPS52110835A (en) * | 1976-03-11 | 1977-09-17 | Microbial Chem Res Found | Remedy for immunological diseases containing benzanilide derivative as active ingredient |
GB2031410A (en) * | 1978-08-25 | 1980-04-23 | Provesan Sa | New derivatives of 1,3- benzoxazine-2,4-dione, their preparation and their application as medicaments |
WO1999065449A2 (en) * | 1998-06-19 | 1999-12-23 | Smithkline Beecham Corporation | INHIBITORS OF TRANSCRIPTION FACTOR NF-λB |
JP2000169479A (ja) * | 1998-12-09 | 2000-06-20 | Kyowa Hakko Kogyo Co Ltd | NF−κB活性化阻害剤 |
WO2001000213A1 (en) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
WO2001012588A1 (fr) * | 1999-08-11 | 2001-02-22 | Mercian Corporation | Derives de salicylamide |
WO2001044217A1 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Aminothiazole inhibitors of cyclin dependent kinases |
WO2002049632A1 (fr) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibiteurs de production et de liberation de cytokines inflammatoires |
WO2002076918A1 (en) * | 2001-03-27 | 2002-10-03 | Suntory Limited | NF-λB INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US14811A (en) * | 1856-05-06 | Process of preparing elastic india-rubber cloth | ||
US19412A (en) * | 1858-02-23 | Improvement in shovel-plows | ||
US48891A (en) * | 1865-07-25 | Improved vessel for holding petroleum | ||
US122244A (en) * | 1871-12-26 | Improvement in fire-extinguishers | ||
US2199A (en) * | 1841-07-29 | Improvement in the manufacture of buttons | ||
US157844A (en) * | 1874-12-15 | Improvement in steam x c cylinder lubricators | ||
US259877A (en) * | 1882-06-20 | Under-garment for infants | ||
US19958A (en) * | 1858-04-13 | Improvement in raking attachments to harvesters | ||
US69267A (en) * | 1867-09-24 | Improved means for extinguishing fire in steamships | ||
US165398A (en) * | 1875-07-06 | Improvement in processes for cleansing gas-retorts | ||
US87650A (en) * | 1869-03-09 | Improvement in the manufacture of artificial fuel | ||
JPS37225B1 (ja) | 1958-07-23 | 1962-01-23 | ||
NL292958A (ja) | 1962-05-29 | 1900-01-01 | ||
GB1099865A (en) | 1965-10-11 | 1968-01-17 | Stecker Internat S P A | Benzoazinediones and germicidal compositions made therewith |
JPS5673054A (en) * | 1979-11-20 | 1981-06-17 | Hodogaya Chem Co Ltd | Benzamide derivative and herbicide containing the same |
US4358443A (en) | 1980-04-14 | 1982-11-09 | The Research Foundation Of State University Of New York | Method and composition for controlling the growth of microorganisms |
JPS56156251A (en) * | 1980-05-06 | 1981-12-02 | Hodogaya Chem Co Ltd | Benzamide derivative and herbicide comprising it |
CA1219587A (en) | 1981-12-14 | 1987-03-24 | Norman P. Jensen | Hydroxybenzylaminobenzenes as anti-inflammatory agents |
JPS59118750A (ja) | 1982-12-27 | 1984-07-09 | Eisai Co Ltd | カルボン酸アミド化合物およびその誘導体 |
US4725590A (en) | 1983-08-24 | 1988-02-16 | Lever Brothers Company | Method of relieving pain and inflammatory conditions employing substituted salicylamides |
US4742083A (en) | 1983-08-24 | 1988-05-03 | Lever Brothers Company | Method of relieving pain and inflammatory conditions employing substituted salicylamides |
JPS6299329A (ja) * | 1983-08-24 | 1987-05-08 | ユニリ−バ−・ナ−ムロ−ゼ・ベンノ−トシヤ−プ | 皮膚用抗炎症組成物 |
US4560549A (en) | 1983-08-24 | 1985-12-24 | Lever Brothers Company | Method of relieving pain and inflammatory conditions employing substituted salicylamides |
JPS6230780A (ja) | 1985-04-17 | 1987-02-09 | Ss Pharmaceut Co Ltd | 1,7−ナフチリジン誘導体及びこれを含有する薬剤 |
US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
JPH0755902B2 (ja) | 1986-10-21 | 1995-06-14 | 株式会社ツムラ | アルド−スリダクタ−ゼ阻害剤 |
JPS6487491A (en) | 1987-09-30 | 1989-03-31 | Hitachi Ltd | Guide apparatus for passenger conveyor |
JPH01121225A (ja) | 1987-11-02 | 1989-05-12 | Agency Of Ind Science & Technol | エチレン性不飽和化合物の製造方法 |
US4786644A (en) | 1987-11-27 | 1988-11-22 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinolinecarboxamide |
US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
JP2988739B2 (ja) | 1990-04-16 | 1999-12-13 | 協和醗酵工業株式会社 | 1,8−ナフチリジン−2−オン誘導体 |
JPH04217916A (ja) | 1990-06-21 | 1992-08-07 | Japan Tobacco Inc | 抗炎症剤 |
AU641052B2 (en) | 1990-11-02 | 1993-09-09 | Aventisub Ii Inc. | 3-amidoindolyl derivatives |
US5192753A (en) | 1991-04-23 | 1993-03-09 | Mcgeer Patrick L | Anti-rheumatoid arthritic drugs in the treatment of dementia |
CZ285937B6 (cs) | 1992-01-16 | 1999-12-15 | Hoechst Aktiengesellschaft | Arylcykloalkylové deriváty, způsob přípravy těchto derivátů a jejich použití |
US6159988A (en) | 1992-01-16 | 2000-12-12 | Hoeschst Aktiengesellschaft | Arylcycloalkyl derivatives, their production and their use |
JP2546622B2 (ja) | 1994-02-14 | 1996-10-23 | オリエント時計株式会社 | 複合混合多層膜 |
WO1996017832A1 (en) | 1994-12-07 | 1996-06-13 | Warner-Lambert Company | Novel glutamate receptor antagonists: fused cycloalkylquinoxalinediones |
JPH08175990A (ja) | 1994-12-19 | 1996-07-09 | Mitsubishi Chem Corp | Pi3キナーゼ阻害剤とその製造法 |
DE19505751A1 (de) * | 1995-02-20 | 1996-08-22 | Basf Ag | Wäßrige Alkyldiketen-Dispersionen und ihre Verwendung als Leimungsmittel für Papier |
US5852028A (en) | 1995-12-18 | 1998-12-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
CA2230894A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
JPH09169747A (ja) | 1995-12-18 | 1997-06-30 | Kyorin Pharmaceut Co Ltd | 新規置換フェニルチアゾリジン−2,4−ジオン誘導体及びその製造法 |
JPH09203951A (ja) | 1996-01-26 | 1997-08-05 | Minolta Co Ltd | カートリッジホルダーの防水機構 |
JPH09227561A (ja) | 1996-02-21 | 1997-09-02 | Tanabe Seiyaku Co Ltd | キサンチン誘導体 |
JPH1045738A (ja) | 1996-07-29 | 1998-02-17 | Microbial Chem Res Found | 抗生物質エポキシキノマイシンcおよびdとその製造法ならびに抗リウマチ剤 |
ITMI962356A1 (it) | 1996-11-13 | 1998-05-13 | Uni Degli Studi Di Brescia D I | Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di |
ES2242995T3 (es) * | 1997-01-15 | 2005-11-16 | Telik, Inc. | Moduladores de la actividad del receptor de la insulina. |
JPH1121243A (ja) | 1997-05-06 | 1999-01-26 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JP3840317B2 (ja) | 1997-08-01 | 2006-11-01 | シーケーディ株式会社 | 手動機構付エアオペレイト弁 |
US6117859A (en) | 1997-11-04 | 2000-09-12 | The Research Foundation Of State University Of New York | Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
JPH11180873A (ja) | 1997-12-22 | 1999-07-06 | Kaken Shoyaku Kk | NF−κB活性阻害剤 |
JPH11217361A (ja) | 1998-01-29 | 1999-08-10 | Fuji Photo Film Co Ltd | ナフトキノン化合物及び該化合物からなる医薬 |
WO1999040907A1 (en) * | 1998-02-13 | 1999-08-19 | Medinox, Inc. | Methods for the controlled delivery of carbon disulfide for the treatment of inflammatory conditions |
JP2000080041A (ja) | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
US6225329B1 (en) | 1998-03-12 | 2001-05-01 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPases) |
US20020002199A1 (en) | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
US20020019412A1 (en) | 1998-03-12 | 2002-02-14 | Henrik Sune Andersen | Modulators of protein tyrosine phosphatases (ptpases) |
AU2713699A (en) * | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
AU2713799A (en) * | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
US6262044B1 (en) | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
ATE308546T1 (de) | 1998-03-12 | 2005-11-15 | Novo Nordisk As | Modulatoren der protein tyrosin phosphatase (ptpases) |
WO1999046267A1 (en) * | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
CN1181817C (zh) | 1998-03-20 | 2004-12-29 | 第一三得利制药株式会社 | 以苯基甲苯醌为有效成分的NF-kB抑制剂 |
WO2000005234A1 (fr) | 1998-07-22 | 2000-02-03 | Suntory Limited | INHIBITEURS DE NF-λB CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF |
JP4748338B2 (ja) * | 1998-09-11 | 2011-08-17 | 味の素株式会社 | ベンゼン誘導体及びその医薬用途 |
US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
AU6471300A (en) | 1999-08-06 | 2001-03-05 | Takeda Chemical Industries Ltd. | P38map kinase inhibitors |
PT1088819E (pt) | 1999-09-30 | 2005-09-30 | Pfizer Prod Inc | Derivados de 6-azauracilo como lignados de receptores da tiroide |
US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
US6706766B2 (en) | 1999-12-13 | 2004-03-16 | President And Fellows Of Harvard College | Small molecules used to increase cell death |
US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
EP1182251A1 (en) * | 2000-08-11 | 2002-02-27 | Yissum Research Development Company of the Hebrew University of Jerusalem | Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB |
WO2002051397A1 (fr) | 2000-12-22 | 2002-07-04 | Ishihara Sangyo Kaisha, Ltd. | Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives |
CA2487891A1 (en) | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
CN1658854A (zh) | 2002-06-05 | 2005-08-24 | 株式会社医药分子设计研究所 | 免疫关联蛋白激酶抑制剂 |
CA2488367A1 (en) | 2002-06-06 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
CA2488974A1 (en) | 2002-06-10 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of cancer |
US20060089395A1 (en) * | 2002-06-10 | 2006-04-27 | Susumu Muto | Nf-kb activation inhibitors |
EA011707B1 (ru) * | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
-
2003
- 2003-06-05 JP JP2004510775A patent/JP4743382B2/ja not_active Expired - Fee Related
- 2003-06-05 KR KR1020047019766A patent/KR101118807B1/ko not_active IP Right Cessation
- 2003-06-05 US US10/515,622 patent/US7626042B2/en not_active Expired - Fee Related
- 2003-06-05 CA CA2488363A patent/CA2488363C/en not_active Expired - Fee Related
- 2003-06-05 CN CN038129442A patent/CN1658855B/zh not_active Expired - Fee Related
- 2003-06-05 EP EP03730837.6A patent/EP1512397B1/en not_active Expired - Lifetime
- 2003-06-05 TW TW092115281A patent/TW200406198A/zh unknown
- 2003-06-05 EA EA200401614A patent/EA009051B1/ru not_active IP Right Cessation
- 2003-06-05 AU AU2003242118A patent/AU2003242118B2/en not_active Ceased
- 2003-06-05 KR KR1020117004044A patent/KR20110028554A/ko not_active Application Discontinuation
- 2003-06-05 WO PCT/JP2003/007127 patent/WO2003103656A1/ja active Application Filing
-
2009
- 2009-10-14 US US12/579,168 patent/US20100113770A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1481713A (fr) * | 1965-10-11 | 1967-05-19 | Stecker Internat S P A | Benzoazinediones et compositions germicides qui les contiennent |
US3906023A (en) * | 1971-04-28 | 1975-09-16 | Bayer Ag | Substituted-2-alkoxycarbonyloxy benzoic acid anilides |
JPS52110835A (en) * | 1976-03-11 | 1977-09-17 | Microbial Chem Res Found | Remedy for immunological diseases containing benzanilide derivative as active ingredient |
GB2031410A (en) * | 1978-08-25 | 1980-04-23 | Provesan Sa | New derivatives of 1,3- benzoxazine-2,4-dione, their preparation and their application as medicaments |
WO1999065449A2 (en) * | 1998-06-19 | 1999-12-23 | Smithkline Beecham Corporation | INHIBITORS OF TRANSCRIPTION FACTOR NF-λB |
JP2000169479A (ja) * | 1998-12-09 | 2000-06-20 | Kyowa Hakko Kogyo Co Ltd | NF−κB活性化阻害剤 |
WO2001000213A1 (en) * | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
WO2001012588A1 (fr) * | 1999-08-11 | 2001-02-22 | Mercian Corporation | Derives de salicylamide |
WO2001044217A1 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Aminothiazole inhibitors of cyclin dependent kinases |
WO2002049632A1 (fr) * | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibiteurs de production et de liberation de cytokines inflammatoires |
WO2002076918A1 (en) * | 2001-03-27 | 2002-10-03 | Suntory Limited | NF-λB INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT |
Non-Patent Citations (3)
Title |
---|
HSI RICHARD S.P. ET AL.: "Hydrolysis of salicylanilide carbamates", JOURNAL OF ORGANIC CHEMISTRY, vol. 37, no. 22, 1972, pages 3427 - 3431, XP002972324 * |
KLOSA J.: "Synthesis of amides from alkoxybenzoic acids and 4-amino-1-phenyl-2,3-dimethyl-5-pyrazolone", JOURNAL FUER PRAKTISCHE CHEMIE, vol. 25, no. 1-2, 1964, LEIPZIG, pages 48 - 55, XP002972325 * |
WEST S, ET AL.: "A multiple-staining procedure for the detection of different DNA fragments on a single blot", ANALYTICAL BIOCHEMISTRY, vol. 190, no. 2, 1990, pages 254 - 258, XP002972326 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601840B2 (en) | 2004-03-15 | 2009-10-13 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
US8143257B2 (en) | 2004-11-23 | 2012-03-27 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting VEGF production |
WO2006065479A3 (en) * | 2004-11-23 | 2006-08-03 | Ptc Therapeutics Inc | Substituted phenols as active agents inhibiting vegf production |
JP2008520740A (ja) * | 2004-11-23 | 2008-06-19 | ピーティーシー セラピューティクス, インコーポレイテッド | Vegf産生を阻害する活性因子としての置換されたフェノール |
WO2006065479A2 (en) * | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Substituted phenols as active agents inhibiting vegf production |
US7671058B2 (en) | 2006-06-21 | 2010-03-02 | Institute Of Medicinal Molecular Design, Inc. | N-(3,4-disubstituted phenyl) salicylamide derivatives |
JP2015520151A (ja) * | 2012-05-08 | 2015-07-16 | エアロミクス・リミテッド・ライアビリティ・カンパニーAeromics,LLC | 新規方法 |
JP2018016647A (ja) * | 2012-05-08 | 2018-02-01 | エアロミクス・インコーポレイテッドAeromics,Inc. | 新規方法 |
JP2016535787A (ja) * | 2013-11-06 | 2016-11-17 | エアロミクス・インコーポレイテッドAeromics,Inc. | 新規方法 |
JP2016536370A (ja) * | 2013-11-06 | 2016-11-24 | エアロミクス・インコーポレイテッドAeromics,Inc. | 新規製剤 |
JP2019163314A (ja) * | 2013-11-06 | 2019-09-26 | エアロミクス・インコーポレイテッドAeromics,Inc. | 新規製剤 |
JP2022003084A (ja) * | 2013-11-06 | 2022-01-11 | エアロミクス・インコーポレイテッドAeromics, Inc. | 新規製剤 |
JP2019521086A (ja) * | 2016-05-13 | 2019-07-25 | エアロミクス・インコーポレイテッドAeromics,Inc. | 結晶 |
WO2021114313A1 (en) * | 2019-12-14 | 2021-06-17 | Shanghai East Hospital | Ion channel antagonists/blockers and uses thereof |
CN114401935A (zh) * | 2019-12-14 | 2022-04-26 | 上海市东方医院(同济大学附属东方医院) | 离子通道拮抗剂/阻断剂及其用途 |
CN114401935B (zh) * | 2019-12-14 | 2024-04-05 | 上海市东方医院(同济大学附属东方医院) | 离子通道拮抗剂/阻断剂及其用途 |
Also Published As
Publication number | Publication date |
---|---|
TW200406198A (en) | 2004-05-01 |
CN1658855B (zh) | 2010-04-28 |
US20060094718A1 (en) | 2006-05-04 |
EA200401614A1 (ru) | 2005-06-30 |
KR20050023288A (ko) | 2005-03-09 |
EP1512397B1 (en) | 2014-10-08 |
EP1512397A4 (en) | 2009-01-07 |
AU2003242118A1 (en) | 2003-12-22 |
US20100113770A1 (en) | 2010-05-06 |
KR20110028554A (ko) | 2011-03-18 |
US7626042B2 (en) | 2009-12-01 |
KR101118807B1 (ko) | 2012-04-12 |
CA2488363C (en) | 2011-01-04 |
CN1658855A (zh) | 2005-08-24 |
AU2003242118B2 (en) | 2008-09-11 |
EA009051B1 (ru) | 2007-10-26 |
EP1512397A1 (en) | 2005-03-09 |
JP4743382B2 (ja) | 2011-08-10 |
CA2488363A1 (en) | 2003-12-18 |
JPWO2003103656A1 (ja) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003103656A1 (ja) | O−置換ヒドロキシアリール誘導体 | |
JP4405602B2 (ja) | ヒストン脱アセチル化酵素阻害剤 | |
EP1437346B9 (en) | Benzamide derivatives useful as cell differentiation inducers | |
AU2009331179B2 (en) | Novel bicyclic heterocyclic compound | |
JP3259915B2 (ja) | 新規な置換されたサリチル酸 | |
WO2003103654A1 (ja) | NF−κB活性化阻害剤 | |
WO2003103658A1 (ja) | 免疫関連プロテインキナーゼ阻害剤 | |
UA82827C2 (en) | Inhibitors against the production and release of inflammatory cytokines | |
WO2003103657A1 (ja) | 神経変性疾患治療剤 | |
JP2006518341A (ja) | ヒストンデアセチラーゼ(hdac)阻害剤としてのヒドロキサム酸誘導体 | |
JPWO2003033493A1 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
JPH11335375A (ja) | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 | |
WO2007142323A1 (ja) | 側鎖にスピロ環構造を有する新規インダゾール誘導体 | |
PT1689726E (pt) | Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores | |
WO2012109544A1 (en) | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators | |
CN111943906B (zh) | 脒类衍生物、及其制法和药物组合物与用途 | |
JP3215850B2 (ja) | ハロアルコキシ基を含有するピロロ[3,2―c]キノリン誘導体及び薬学的に許容されるその塩 | |
WO2019200502A1 (zh) | 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物 | |
KR101440255B1 (ko) | 치환 페닐알칸산의 신규 결정 및 제조 방법 | |
WO2006132438A1 (ja) | 1,3-ベンゾチアジノン誘導体およびその用途 | |
WO2017098733A1 (ja) | インドール酢酸誘導体 | |
JPH11152286A (ja) | フェニルアルカン酸エステルの塩酸塩、およびその製造方法 | |
WO2021028935A1 (en) | Heterocyclic compounds, and their use as allosteric modulators of 5-hydroxytryptamine 2c receptor (5-ht2cr) | |
CN114456123A (zh) | Fxr调节剂及其制备方法和用途 | |
CN118026948A (zh) | 三联芳环类化合物及其制备方法、药物组合物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004510775 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038129442 Country of ref document: CN Ref document number: 1020047019766 Country of ref document: KR Ref document number: 2488363 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003242118 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003730837 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200401614 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047019766 Country of ref document: KR Ref document number: 2003730837 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006094718 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10515622 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10515622 Country of ref document: US |